WO2019152827A1 - Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof - Google Patents
Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof Download PDFInfo
- Publication number
- WO2019152827A1 WO2019152827A1 PCT/US2019/016325 US2019016325W WO2019152827A1 WO 2019152827 A1 WO2019152827 A1 WO 2019152827A1 US 2019016325 W US2019016325 W US 2019016325W WO 2019152827 A1 WO2019152827 A1 WO 2019152827A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- fusion molecule
- albumin
- seq
- fragment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000000611 antibody drug conjugate Substances 0.000 title abstract description 25
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 350
- 229940079593 drug Drugs 0.000 claims abstract description 347
- 102000009027 Albumins Human genes 0.000 claims abstract description 343
- 108010088751 Albumins Proteins 0.000 claims abstract description 343
- 239000012634 fragment Substances 0.000 claims abstract description 336
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 309
- 230000004927 fusion Effects 0.000 claims abstract description 303
- 230000021615 conjugation Effects 0.000 claims abstract description 250
- 239000000427 antigen Substances 0.000 claims abstract description 187
- 102000036639 antigens Human genes 0.000 claims abstract description 187
- 108091007433 antigens Proteins 0.000 claims abstract description 187
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 104
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 128
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 150000001413 amino acids Chemical class 0.000 claims description 110
- 235000001014 amino acid Nutrition 0.000 claims description 108
- 125000000539 amino acid group Chemical group 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- NLMBVBUNULOTNS-HOKPPMCLSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl n-[(2s)-1-[[(2s)-1-[[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-o Chemical group C1([C@H](O)[C@@H](C)NC(=O)[C@H](C)[C@@H](OC)[C@@H]2CCCN2C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC=2C=CC(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN3C(C=CC3=O)=O)C(C)C)=CC=2)C(C)C)OC)=CC=CC=C1 NLMBVBUNULOTNS-HOKPPMCLSA-N 0.000 claims description 17
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 239000002254 cytotoxic agent Substances 0.000 claims description 16
- 239000003638 chemical reducing agent Substances 0.000 claims description 15
- 230000001268 conjugating effect Effects 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 235000014304 histidine Nutrition 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 235000009697 arginine Nutrition 0.000 claims description 8
- 235000018977 lysine Nutrition 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 101150040459 RAS gene Proteins 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 239000007800 oxidant agent Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 230000034701 macropinocytosis Effects 0.000 claims description 3
- 102220105280 rs879254406 Human genes 0.000 claims description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 abstract description 29
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 28
- 239000000562 conjugate Substances 0.000 abstract description 12
- 229940024606 amino acid Drugs 0.000 description 103
- 108020001507 fusion proteins Proteins 0.000 description 42
- 125000003275 alpha amino acid group Chemical group 0.000 description 36
- 102000037865 fusion proteins Human genes 0.000 description 36
- 102000010956 Glypican Human genes 0.000 description 30
- 108050001154 Glypican Proteins 0.000 description 30
- 108050007237 Glypican-3 Proteins 0.000 description 30
- -1 succinimide thioether Chemical class 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 239000000872 buffer Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 19
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 102000002029 Claudin Human genes 0.000 description 10
- 108050009302 Claudin Proteins 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 239000001488 sodium phosphate Substances 0.000 description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 102100036466 Delta-like protein 3 Human genes 0.000 description 5
- 101710112748 Delta-like protein 3 Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 229960000455 brentuximab vedotin Drugs 0.000 description 5
- 229960005395 cetuximab Drugs 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229960001972 panitumumab Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000001990 protein-drug conjugate Substances 0.000 description 5
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 108010059074 monomethylauristatin F Proteins 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 229960002317 succinimide Drugs 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 3
- 229930195731 calicheamicin Natural products 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 3
- 229960005501 duocarmycin Drugs 0.000 description 3
- 229930184221 duocarmycin Natural products 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- OMRPLUKQNWNZAV-CONSDPRKSA-N (6as)-3-[3-[[(6as)-2-methoxy-8-(4-methoxyphenyl)-11-oxo-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-8-(4-aminophenyl)-2-methoxy-6a,7-dihydropyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound C1=CC(OC)=CC=C1C1=CN2C(=O)C3=CC(OC)=C(OCCCOC=4C(=CC=5C(=O)N6C=C(C[C@H]6C=NC=5C=4)C=4C=CC(N)=CC=4)OC)C=C3N=C[C@@H]2C1 OMRPLUKQNWNZAV-CONSDPRKSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- INZOTETZQBPBCE-NYLDSJSYSA-N 3-sialyl lewis Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@H](O)CO)[C@@H]([C@@H](NC(C)=O)C=O)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 INZOTETZQBPBCE-NYLDSJSYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
- 102100033553 Delta-like protein 4 Human genes 0.000 description 2
- 101710112728 Delta-like protein 4 Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000013128 Endothelin B Receptor Human genes 0.000 description 2
- 108010090557 Endothelin B Receptor Proteins 0.000 description 2
- 239000004277 Ferrous carbonate Substances 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 2
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 description 2
- 101710117181 SLIT and NTRK-like protein 6 Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 2
- 101710190034 Trophoblast glycoprotein Proteins 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 108010019521 carbonic anhydrase VI Proteins 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000034778 micropinocytosis Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- APOKYMYZOKIMLM-LUMVZWMBSA-N (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[4-[[(2s,3s,4s,6r)-3-hydroxy-2-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]oxan-4-yl]carbamoyloxymethyl]-2-nitrophenoxy]oxane-2-carboxylic acid Chemical compound N([C@H]1C[C@@H](O[C@@H](C)[C@H]1O)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C(=O)OCC(C=C1[N+]([O-])=O)=CC=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O APOKYMYZOKIMLM-LUMVZWMBSA-N 0.000 description 1
- URCVASXWNJQAEH-HDWVWLDDSA-N (2s,3s,4s,5r,6s)-6-[4-[(5s,5ar,8ar,9r)-5-[[(2r,4ar,6r,7r,8r,8as)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenoxy]-3,4,5-trihydrox Chemical compound COC1=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=CC(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O URCVASXWNJQAEH-HDWVWLDDSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100034231 Cell surface A33 antigen Human genes 0.000 description 1
- 101710165668 Cell surface A33 antigen Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 102100038449 Claudin-6 Human genes 0.000 description 1
- 108090000229 Claudin-6 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 1
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 1
- 101600074231 Homo sapiens Sodium-dependent phosphate transport protein 2B (isoform 2) Proteins 0.000 description 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100035486 Nectin-4 Human genes 0.000 description 1
- 101710043865 Nectin-4 Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 229940122277 RNA polymerase inhibitor Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100029197 SLAM family member 6 Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102300065209 Sodium-dependent phosphate transport protein 2B isoform 2 Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100035721 Syndecan-1 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- QQOBRRFOVWGIMD-OJAKKHQRSA-N azaribine Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=N1 QQOBRRFOVWGIMD-OJAKKHQRSA-N 0.000 description 1
- 229950010054 azaribine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Definitions
- the present application relates to novel antibody-drug conjugates (ADC), including antibody-albumin-drug conjugates (AADC). Further included in the present application are methods of using the novel antibody-drug conjugates and antibody-albumin-drug conjugates
- Antibody-drug conjugates allow for targeted delivery of a therapeutic agent, particularly to cancer cells, which can reduce side-effects commonly associated with chemotherapy.
- the antibody portion of the ADC can also allow for biological modulation that further enhances the efficacy of the conjugated drug.
- the drug molecule is generally conjugated through a cleavable or non-cleavable linker that attaches to a cysteine or lysine on the antibody molecule.
- the drug to antibody ration (DAR) of the ADC is limited, in part, by the number of moieties within the antibody that the drug can be linked to and the
- antibody fusion molecules including antibody fusion molecules conjugated to a payload molecule, such as a drug molecule (e.g., a cytotoxic drug molecule). Also described are methods of making such antibody fusion molecules and methods of treating a disease in a subject comprising administering an effective amount of the antibody fusion molecule to the subject.
- a payload molecule such as a drug molecule (e.g., a cytotoxic drug molecule).
- the antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain and an antibody light chain, or a fragment thereof, and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof wherein the drug conjugation moiety comprises a heterologous peptide (Pl) less than about 50 amino acids in length, and wherein Pl comprises a cysteine residue.
- the heterologous peptide (Pl) is about 5 to about 20 amino acids in length.
- the antigen-binding moiety binds to one or more antigen on a surface of a cancer cell.
- the cancer cell has upregulated
- the cancer cell comprises one or more mutant RAS family genes.
- the heterologous peptide (Pl) is unstructured or is helical.
- the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody heavy chain, or the fragment thereof. In some embodiments, the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody light chain, or the fragment thereof.
- the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment.
- the drug conjugation moiety comprises an albumin, or an albumin fragment, fused to Pl.
- the cysteine residue of Pl is about 30 amino acid residues or less away from a first residue a last residue of the albumin or the albumin fragment.
- the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the albumin or the albumin fragment.
- the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via Pl.
- the albumin or the albumin fragment has a point mutation at Cys34.
- the point mutation is Cys34Ser.
- the drug conjugation moiety comprises a full length albumin.
- the drug conjugation moiety comprises the albumin fragment.
- the albumin has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.
- the drug conjugation moiety comprises a second heterologous peptide (P2), which is fused to the albumin or albumin fragment.
- the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the second heterologous peptide (P2).
- the second heterologous peptide (P2) comprises a cysteine residue.
- the second heterologous peptide (P2) does not comprise a cysteine residue.
- the second heterologous peptide (P2) is helical or unstructured.
- the second heterologous peptide (P2) is about 5 to about 20 amino acid residues in length.
- the second heterologous peptide (P2) comprises one or more glycine residues or one or more serine residues. In some embodiments, the second heterologous peptide (P2) comprises an amino acid sequence of (GGGGS) q (SEQ ID NO: 34), wherein q is 1 or more.
- the second heterologous peptide (P2) comprises an amino acid sequence of (GGGGS) q (SEQ ID NO: 34), wherein q is 1, 2, 3, or 4.
- the drug conjugation moiety comprises two or more albumins or albumin fragments. In some embodiments, the drug conjugation moiety comprises three or more heterologous peptides. In some embodiments, each of the heterologous peptides comprises a cysteine residue.
- the antibody fusion molecules comprising a polypeptide configured, from N-terminus to C-terminus, according to:
- HL is the antibody heavy chain or the antibody light chain, or the fragment thereof; wherein Pl, P3, P4, and P5 are heterologous peptides, wherein at least one of Pl, P3, P4, and P5 comprises a cysteine residue; wherein P2 is a heterologous peptide; and wherein A is an albumin or a fragment thereof.
- each of Pl, P3, P4, and P5 is about 5 to about 20 amino acid residues in length, and Pl, P3, P4, and P5 are of the same length or of different lengths.
- at least one of Pl, P3, P4, and P5 comprises at least one charged amino acid.
- at least one of Pl, P3, P4, and P5 comprises one or more positively charged amino acid residues.
- the one or more positively charged amino acid residues are selected from the group consisting of lysine, histidine, arginine, and combinations thereof.
- at least one of Pl, P3, P4, and P5 comprises one or more negatively charged amino acid residues.
- the one or more negatively charged amino acid residues are selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
- At least one of Pl, P3, P4, and P5 comprises a sequence according to:
- Xaai, Xaa 2 , Xaa 3 , Xaa 4 , Xaa 3 , and Xaa 6 comprise at least one positively charged amino acid residue and no negatively charged amino acid residues; or at least one negatively charged amino acid residue and no positively charged amino acid residues.
- Xaai, Xaa 2 , Xaa 3 , Xaa4, Xaa 3 , and Xaa 6 are each either (1) selected from the group consisting of histidine, lysine, arginine, aspartic acid, glutamic acid, glycine, serine, and threonine; or (2) none.
- the antibody fusion molecule comprises a full length antibody heavy chain or a full length antibody light chain.
- the antibody fusion molecule comprises a first drug
- the antibody fusion molecule comprises a first drug
- conjugation moiety fused to a first antibody heavy chain, and a second drug conjugation moiety fused to a second antibody heavy chain, and wherein the first drug conjugation moiety and the second drug conjugation moiety are the same or different.
- the antibody fusion molecule comprises a first drug
- conjugation moiety fused to a first antibody light chain, and a second drug conjugation moiety fused to a second antibody light chain, and wherein the first drug conjugation moiety and the second drug conjugation moiety are the same or different.
- the antibody fusion molecule further comprises a payload molecule covalently bound to the cysteine residue in any one or more of Pl, P3, P4, and P5.
- the payload molecule is covalently bound to the cysteine residue in Pl, P3, P4, or P5 through a conjugation linker.
- the payload molecule is a drug molecule. In some embodiments, the payload molecule is a drug molecule.
- the drug molecule is a cytotoxic drug molecule. In some embodiments, the drug molecule is an anti- viral agent or an anti-bacterial agent. In some embodiments, the payload molecule is an imaging agent.
- the antibody fusion molecule comprises 2-30 payload molecules.
- the conjugation linker binds to the cysteine in Pl, P3, P4, or P5 through a maleimide moiety.
- the maleimide moiety is a N-alkyl maleimide moiety.
- the conjugation linker is bound to two or more payload molecules.
- the drug molecule is a microtubule disrupting agent, a DNA modifying agents, an RNA polymerase inhibitors, or a topoisomerase I inhibitor.
- the conjugation linker is not cleavable. In some embodiments, the conjugation linker is cleavable.
- the conjugation linker comprises amino acids valine-alanine or valine-citrulline.
- the conjugation linker and drug has a structure of:
- z is 4-24; and wherein the maleimide group is covalently attached to the cysteine in any one of Pl, P3, P4, or P5 through the maleimide group.
- binding of the conjugation linker to the cysteine residue in Pl, P3, P4, or P5 results in a ring-opened counterpart of a hydrolyzed succinimide thioether formed by maleimide-thiol conjugation.
- a pharmaceutical composition comprising any of the antibody fusion molecules described above, and a pharmaceutically acceptable excipient.
- a method of treating a cancer in a subject comprising administering to the subject with cancer an effective amount of the pharmaceutical composition, wherein the payload molecule is a cytotoxic drug.
- the cancer expresses an antigen targeted by the antibody or fragment thereof, and comprises a mutant RAS gene.
- the payload molecule is conjugated to cysteine residue in Pl, P3, P4, or P5 through a conjugation linker.
- the conjugation linker is conjugated to the payload molecule prior to conjugating the conjugation linker to the cysteine residue in Pl, P3, P4, or P5.
- the conjugation linker is conjugated to the antibody fusion molecule prior to conjugating the conjugation linker to the drug molecule.
- two or more drug molecules are conjugated to the conjugation linker.
- the conjugation linker comprises a maleimide group.
- the method comprises mixing the antibody fusion molecule with a reducing agent prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method comprises removing the reducing agent prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method comprises mixing the antibody fusion molecule with an oxidizing agent after mixing the antibody fusion molecule with the reducing agent, and prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method comprises removing the oxidizing agent prior to conjugating the payload molecule to the fusion molecule.
- FIG. 1 illustrates the chemical structure of an exemplary drug with conjugating linker, namely MC-vc-PAB-MMAE, which can be conjugated to an antibody fusion molecule.
- FIG. 2 shows a hydrophobic interaction chromatography, high performance liquid chromatography (HIC-HPLC) chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC -vc-PAB-MMAE under storage buffer conditions (2 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7) (bottom panel).
- HIC-HPLC high performance liquid chromatography
- FIG. 3 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) (bottom panel).
- FIG. 4 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0 after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 2.5x molar ratio (TCEP to protein) (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 2.3.
- TCEP tris(2-carboxyethyl)phosphine
- FIG. 5 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 20x molar ratio (TCEP to protein) (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 3.3.
- FIG. 5 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4
- FIG. 6 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 20x molar ratio (TCEP to protein), and then oxidized using ascorbic acid (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 4.5.
- TCEP tris(2-carboxyethyl)phosphine
- An antibody fusion molecule includes an antigen-binding moiety, which may include, for example, an antibody heavy chain and an antibody light chain, which binds to an antigen on a cell surface. Fused to the antigen-binding moiety or a polypeptide component of the antigen binding moiety, there is a drug conjugation moiety.
- the drug conjugation moiety includes a heterologous peptide that includes a cysteine residue, which can be conjugated to the drug.
- the antigen-binding moiety targets the drug to the cell by binding the antigen, which internalizes the antibody fusion molecule. Through this mechanism, the antibody fusion molecule can target the drug to the cell.
- the heterologous peptide of the drug conjugation moiety is fused to an albumin or an albumin fragment.
- the albumin or albumin fragment may be fused to the C-terminal end or the N-terminal end of the heterologous peptide.
- the albumin or the albumin fragment can bind the drug linked to the heterologous polypeptide, which enhances solubility of the drug. Accordingly, the antibody fusion molecule described herein is particularly beneficial for targeted delivery of hydrophobic payload molecules, such as drug molecules.
- Some embodiments of the present invention include a drug conjugation moiety with a plurality of fused heterologous polypeptides, which allow the drug to antibody ratio to be increased by extending the number of heterologous polypeptides.
- the drug conjugation moiety can optionally include a plurality of albumins or albumin fragments, which can enhance the solubility of the drugs molecules attached to the heterologous polypeptides.
- an albumin or an albumin fragment can be included adjacent to each heterologous polypeptide to support the solubility of the drug molecule attached to that heterologous polypeptide.
- ADCs antibody-drug conjugates
- the drug molecules are generally conjugated directly to the antibody molecule.
- Such configuration limits the number of drug molecules that can be bound to the complex (that is, the drug to antibody ratio) due to the limited number of drug attachment sites on the antibody molecule. Additionally, attaching hydrophobic drugs to an antibody molecule can result in decreased solubility and stability of the complex.
- an antibody fusion molecule comprising an antigen-binding moiety, and a drug conjugation moiety fused to the antigen-binding domain, wherein the drug conjugation moiety comprises a heterologous peptide (Pl), and wherein Pl comprises a cysteine residue.
- Pl is less than about 50 amino acids in length.
- the antigen-binding moiety includes an antibody heavy chain (or a fragment thereof) and an antibody light chain (or a fragment thereof), and the drug conjugation moiety is fused to the antibody heavy chain (or fragment thereof) or the antibody light chain (or fragment thereof). Also described are methods of making the antibody fusion molecule.
- the drug conjugation moiety can be fused to the N-terminus or the C-terminus of the antibody heavy chain or the antibody light chain.
- the drug conjugation moiety includes an albumin or an albumin fragment, which is fused to Pl.
- the drug conjugation moiety includes more than one heterologous peptides, which may be the same or different, or more than one albumins or albumin fragments.
- the heterologous peptide includes a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or shorter. In some embodiments, a payload molecule, such as a cytotoxic drug molecule or any other drug molecule, is conjugated to the heterologous peptide, for example through the cysteine residue. In some embodiments, the antibody fusion molecule comprises 2 or more payload molecules. The payload molecule can be conjugated to the heterologous peptide through a cleavable or a non- cleavable linker.
- the antibody fusion molecule can target an antigen on the surface of the cancer cells, thereby delivering the drug to the cancer.
- the cancer cell has upregulated micropinocytosis compared to a non-cancerous cell.
- the cancer has a RAS mutation, which has been linked to upregulated micropinocytosis.
- Reference to“about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of“X.” Additionally, use of“about” preceding any series of numbers includes“about” each of the recited numbers in that series. For example, description referring to“about X, Y, or Z” is intended to describe“about X, about Y, or about Z.”
- the term“antigen-binding moiety” refers to a polypeptide or a set of interacting polypeptides that specifically bind to an antigen, and includes, but is not limited to, an antibody or antibody fragment, such as a monoclonal antibody, polyclonal, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab', a F(ab') 2 , a Fv, a disulfide linked Fv, a scFv, a single domain antibody (dAb), a diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding fragment thereof, bifunctional hybrid antibodies, a single chain antibody, and a Fc-containing polypeptide, such as an immunoadhesion.
- an antibody or antibody fragment such as a monoclonal antibody, polyclonal, a chimeric antibody, a C
- the antibody may be of any heavy chain isotype (e.g., IgG, IgA, IgM, IgE, or IgD). In some embodiments, the antibody may be of any light chain isotype (e.g., kappa or gamma).
- the antibody may be non-human (e.g., from mouse, goat, or any other animal), fully human, humanized, or chimeric. In some embodiments, the antibody is a derivatized antibody.
- an effective amount refers to an amount of a compound or composition sufficient to treat a specified disorder, condition, or disease, such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms.
- an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation in the cancer.
- the effective amount is an amount sufficient to delay development of a cancer.
- the effective amount is an amount sufficient to prevent or delay recurrence.
- An effective amount can be administered in one or more administrations.
- the effective amount of the drug or composition may: (i) reduce the number of epithelioid cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop the cancer cells infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- the term“fused” or“fusion” in reference to two or more polypeptide sequences refers to joining of the polypeptide sequences through a backbone peptide bond.
- pharmaceutically acceptable when used to refer to a compound or composition means that the compound or composition is suitable for administration to a subject, including a human subject, to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.
- subject refers to a mammal and includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate.
- beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms resulting from a disease, diminishing the extent of a disease, stabilizing a disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of a disease, preventing or delaying the recurrence of a disease, delaying or slowing the progression of a disease, ameliorating a disease state, providing remission (partial or total) of a disease, decreasing the dose of one or more other medications required to treat a disease, delaying the progression of a disease, increasing the quality of life, and/or prolonging survival.
- Treatment is a reduction of a pathological consequence of a disease (such as cancer).
- the methods of the invention contemplate any one or more of these aspects
- the antibody fusion molecule includes an antigen-binding moiety fused to a drug conjugation moiety.
- the antigen-binding moiety includes an antibody heavy chain or a fragment thereof, and an antibody light chain or a fragment thereof.
- the drug conjugation moiety cam be fused to the antibody heavy chain or fragment thereof or the antibody light chain or fragment thereof.
- the drug conjugation moiety includes a
- heterologous peptide which includes a cysteine residue.
- the antigen-binding moiety can be an antibody or a fragment thereof.
- the antigen binding moiety is a full length antibody, a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a Fv fragment, a disulfide linked Fv fragment, or a single chain variable fragment (scFv) fragment.
- the antigen-binding moiety includes a full-length antibody heavy chain or a full-length antibody light chain.
- the antigen-binding moiety includes an antibody heavy chain fragment or an antibody light chain fragment.
- the antigen-binding moiety can bind an antigen on the surface of a cell, such as a cancer cell.
- the antigen-binding moiety is a bispecific antigen-binging moiety, can bind to two different antigens or two different epitopes on the same antigen.
- the antigen-binding moiety binds to Guanyl cyclase C (GCC), carbohydrate antigen 19-9 (CA19-9), glycoprotein A33 (gpA33), mucin 1 (MUC1), carcinoembryonic antigen (CEA), insulin-like growth factor 1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), delta-like protein 3 (DLL3), delta-like protein 4 (DLL4), epidermal growth factor receptor (EGFR), glypican-3 (GPC3), c-MET, vascular endothelial growth factor receptor 1 (VEGFR1) 1, vascular endothelial growth factor receptor 2 (VEGFR2), Nectin-4, Liv-l, glycoprotein NMB (GPNMB), pro state- specific membrane antigen (PSMA), Trop-2, carbonic anhydrase IX (CA9), endothelin B receptor (ETBR), Thomsen-F
- pyrophosphatase/phosphodiesterase family member 3 ENPP3
- mesothelin mesothelin
- TPBG trophoblast glycoprotein
- CD19 CD20, CD22, CD33, CD40, CD56, CD66e, CD70, CD74, CD79b, CD98, CD123, CD138, CD352, programmed death ligand 1 (PD-L1), Claudin 18.2, Claudin 6, or deacetylated b-1-6 polymer of N-acetyl glucosamine (dPNAG).
- the antigen-binding moiety binds to an epidermal growth factor (EGF)-like domain of DLL3.
- EGF epidermal growth factor
- the antigen-binding moiety binds to a Delta/S errate/Lag2 (DSL)-like domain of DLL3. In some embodiments, the antigen-binding moiety binds to an epitope located after the 374th amino acid of GPC3. In some
- the antigen-binding moiety binds to a heparin sulfate glycan of GPC3. In some embodiments, the antigen-binding moiety binds to Claudin 18.2 and does not bind to Claudin 18.1. In some embodiments, the antigen-binding moiety binds to Claudin 18.1 with at least 10 times weaker binding affinity than to Claudin 18.2
- antigen-binding moieties include trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, and fragments thereof.
- the antigen-binding moiety that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to trastuzumab, rituximab, brentuximab, cetuximab, or panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof.
- the antigen-binding moiety has an antibody heavy chain with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the antibody heavy chain of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof.
- the antigen binding moiety has an antibody light chain with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the antibody light chain of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof.
- the antigen-binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a drug molecule is conjugated to the cysteine residue.
- the antigen-binding moiety comprises the six complementarity determining regions (CDRs) of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33, anti-EGFR antibody mAb806, or anti-dPNAG antibody F598,
- CDRs complementarity determining regions
- The“Rabat” Complementarity Determining Regions are based on sequence variability and are the most commonly used (Rabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). “Chothia” CDRs refer to the location of the structural loops (Chothia & Lesk, Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., vol. 196, pp. 901-917 (1987)).
- The“AbM” CDRs represent a compromise between the Rabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software.
- The“Contact” CDRs are based on an analysis of the available complex crystal structures. The residues from each of these CDRs are noted below in Table 1, in reference to common antibody numbering schemes. Unless otherwise specified herein, amino acid number of antibodies refers to the Rabat numbering scheme as described in Rabat et al., supra, including when CDR delineations are made in reference to Rabat, Chothia, AbM, or Contact schemes. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a framework region (FR) or CDR of the variable domain.
- FR framework region
- a heavy-chain variable domain may include a single amino acid insert (residue 52a according to Rabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Rabat) after heavy-chain FR residue 82.
- the Rabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a“standard” Rabat numbered sequence.
- the CDRs are“extended CDRs,” and encompass a region that begins or terminates according to a different scheme.
- an extended CDR can be as follows: F24— F36, F26— F34, or F26— F36 (VF-CDR1); F46— F52, F46— F56, or F50— F55 (VF-CDR2); F91— F97 (VF-CDR3); H47— H55, H47— H65, H50— H55, H53— H58, or H53— H65 (VH-CDR2); and/or H93— H102 (VH-CDR3).
- the antigen-binding domain binds to HER2, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 2, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 3, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 2, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 3.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 2, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 3.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule is conjugated to the cysteine residue.
- the antigen-binding domain binds to CD20, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 4, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 5, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 4, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 5.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 4, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 5.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to CD30, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 6, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 7, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 6, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 7.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 6, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 7. .
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to EGF, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 9, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 8, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 9.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 8, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 9.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule is conjugated to the cysteine residue.
- the antigen-binding domain binds to EGFR, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 10 or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11 or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 10, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 11.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 10, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 11.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to c-MET, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 12, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 13.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 12, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 13.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to GPC3, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 14 or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15 or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 15.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 15.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to Claudin 18.2, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 16, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 17, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 16, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 17.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 16, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 17.
- the antigen-binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to dPNAG, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19, or a fragment thereof.
- the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 18, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 19.
- the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 18, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 19.
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to Trop-2, and comprises a light chain variable region comprising a CDR1 comprising an amino acid sequence of KASQDVSIAVA (SEQ ID NO: 20), a CDR2 comprising an amino acid sequence of SASYRYT (SEQ ID NO: 21), and a CDR3 comprising an amino acid sequence of
- QQHYITPLT (SEQ ID NO: 22); and a heavy chain variable region comprising a CDR1 comprising an amino acid sequence of NYGMN (SEQ ID NO: 23), a CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG (SEQ ID NO: 24), and a CDR3 comprising an amino acid sequence of GGFGSSYWYFDV (SEQ ID NO: 25).
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less.
- the heterologous peptide is fused to an albumin or an albumin fragment.
- a payload molecule such as a drug molecule, is conjugated to the cysteine residue.
- the antigen-binding domain binds to mesothelin, and comprises light chain variable region comprising a CDR1 comprising an amino acid sequence of SASSSVSYMH (SEQ ID NO: 26), a CDR2 comprising an amino acid sequence of DTSKLAS (SEQ ID NO: 27), and a CDR3 comprising an amino acid sequence of
- QQWSGYPLT (SEQ ID NO: 28); and a heavy chain variable region comprising a CDR1 comprising an amino acid sequence of GYTMN (SEQ ID NO: 29), a CDR2 comprising an amino acid sequence of LITP YN GAS S YN QKFRG (SEQ ID NO: 30), and a CDR3 comprising an amino acid sequence of GGYDGRGFDY (SEQ ID NO: 31).
- the antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue.
- the heterologous peptide is about 50 amino acids in length or less.
- the heterologous peptide is fused to an albumin or an albumin fragment.
- a payload molecule such as a drug molecule, is conjugated to the cysteine residue.
- the drug conjugation moiety is a polypeptide that includes at least one heterologous peptide comprising a cysteine residue.
- the drug conjugation moiety further includes one or more albumins or albumin fragment.
- the drug conjugation moiety is fused to the antibody heavy chain or the antibody light chain (or antibody heavy chain fragment or antibody light chain fragment) of the antigen fusion molecule, which may be at the N-terminus or the C-terminus of the antibody heavy chain (or fragment) or antibody light chain (or fragment).
- the heterologous peptide is unstructured. In some embodiments, the heterologous peptide is unstructured.
- the heterologous peptide is helical. In some embodiments, the heterologous peptide does not have a tertiary structure in isolation. In some embodiments, the
- heterologous peptide does not have a biological function.
- the heterologous peptide is synthetically designed, and is not derived from a naturally occurring peptide.
- the heterologous peptide is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid residues in length.
- the heterologous peptide comprises about 50 or fewer, about 45 or fewer, about 40 or fewer, about 35 or fewer, about 30 or fewer, about 25 or fewer, about 20 or fewer, about 15 or fewer, or about 10 or fewer amino acids in length.
- the heterologous peptide is about 5 to about 20 amino acid residues in length, such as about 5 to about 10, about 10 to about 15, or about 15 to about 20 amino acid residues in length. If the antibody fusion molecule includes two or more heterologous peptides, the heterologous peptides can be of the same length or of different lengths.
- the heterologous peptide includes at least one charged amino acid, which may be a positively charged amino acid or a negatively charged amino acid (as determined at physiological pH).
- the positively charged amino acid residue is lysine, histidine, or arginine.
- the negatively charged amino acid residue is aspartic acid or glutamic acid.
- the heterologous peptide has a net negative charge or a net positive charge.
- the heterologous peptide can optionally include one or more (such as 1, 2, 3, or 4) GGGGS (SEQ ID NO: 42) sequences at the N-terminal end, the C-terminal end, or both the N-terminal end and the N-terminal end of the heterologous peptide.
- the heterologous peptide has the sequence:
- the X aai , X aa2, X aa3 , X aa4, X aa5, X aa( resort and X aa7 amino acid residues have a net positive charge or a net negative charge.
- the X aai , X aa2, X aa3 , X aa4, X aa5 , X aaf , and X aa7 amino acid residues include at least one positively charged amino acid residue and no negatively charged amino acid residues.
- the X ⁇ i, X aa2 , X aa3 , X aa4 , X aa5 , X aa(petit and X aa7 amino acid residues include at least one negatively charged amino acid residue and no positively charged amino acid residues.
- the X aa amino acid residues are selected from histidine, lysine, arginine, aspartic acid, glutamic acid, glycine, serine, threonine, and combinations thereof.
- the heterologous peptide can include 1,2 ,3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19, 20 or more X aa amino acid residues. Accordingly, in some embodiments, one or more of the X aa amino acid residues are deleted, and in some embodiments, one or more additional X aa amino acid residues are included between the (GGGGS)n (SEQ ID NO: 44) sequence and the (GGGGS) m (SEQ ID NO: 45) sequence.
- the drug conjugation moiety includes an albumin or a fragment thereof fused to the heterologous peptide.
- the albumin or fragment thereof can be fused to the N-terminal end or the C-terminal end of the heterologous peptide.
- the drug conjugation moiety can be fused to the antibody heavy chain (or fragment) or the antibody light chain (or fragment) via the albumin or albumin fragment or via the heterologous peptide.
- the antibody fusion molecule can include a polypeptide having the configuration HL-A-P (wherein HL indicates the antibody heavy chain (or fragment) or antibody light chain (or fragment), A indicates the albumin (or fragment), and P indicates the heterologous peptide) or the configuration HL-P-A.
- the cysteine residue of the heterologous peptide is about 30,
- the albumin is human albumin or a variant thereof.
- SEQ ID NO: 1 is the sequence of human albumin.
- the albumin or albumin fragment is about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 99% or more, about 99.5% or more, or about 99.8% or more identical to human albumin or a fragment thereof.
- the drug conjugation moiety comprises a full length albumin.
- the drug conjugation moiety comprises an albumin fragment that is about 10 or more, 20 or more, 30 or more 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 120 or more, 140 or more, 160 or more, 180 or more, 200 or more, 250 or more, 300 or more, 350 or more, 400 or more, 450 or more, 500 or more, or 550 or more amino acids in length.
- the albumin fragment is between about 10 amino acids and about 584 amino acids in length (such as between about 10 and about 20, about 20 and about 40, about 40 and about 80, about 80 and about 160, about 160 and about 250, about 250 and about 350, about 350 and about 450, or about 450 and about 550 amino acids in length).
- the albumin fragment includes the Sudlow I domain or a fragment thereof, or the Sudlow II domain or the fragment thereof.
- the albumin or albumin fragment includes one or more (such as 2, 3, 4, 5 or more) point mutations, amino acid insertions, or amino acid deletions.
- the albumin or albumin fragment includes a point mutation at one or more cysteine residues.
- the albumin or albumin fragment includes a point mutation at one or more of Dl, A2, C75, T79, E82, E86, C91, D121, C124, D129, C168, C169, C177, S270, C316, A364, C360, C361, C369, Q397, K500, A504, E505, D549, C558, D562, C567, K573, K574, A578, A581, or L585.
- the albumin or albumin fragment includes a point mutation, insertion, or deletion adjacent to one or more of Dl, A2, C75, T79, E82, E86, C91, D121, C124, D129, C168, C169, C177, S270, C316,
- the albumin or albumin fragment includes a point mutation at Cys34. In some embodiments, the albumin or albumin fragment includes a Cys34Ser point mutation.
- the drug conjugation moiety includes a second heterologous peptide in addition to one or more of the heterologous peptides described above. In some embodiments, the second heterologous peptide includes a cysteine residue. In some embodiments, the second heterologous peptide does not include a cysteine residue.
- the second heterologous peptide is fused to one of the other components of the drug conjugation moiety (i.e., an albumin or albumin fragment, and/or another heterologous peptide).
- the antibody fusion molecule includes a polypeptide having the configuration HL-P2-A-P1 (wherein HL indicates the antibody heavy chain (or fragment) or antibody light chain (or fragment), P2 indicates the second heterologous peptide that may or may not include a cysteine, A indicates the albumin (or fragment), and Pl indicates the heterologous peptide having a cysteine).
- the drug conjugation moiety is fused to the antibody heavy chain (or fragment) or the antibody light chain (or fragment) via the second heterologous peptide (P2), which is fused to the albumin or albumin fragment (A), which is fused to the first heterologous peptide (Pl).
- the second heterologous peptide (P2) is helical. In some embodiments, the second heterologous peptide (P2) is unstructured. In some embodiments, the second heterologous peptide (P2) is helical. In some embodiments, the heterologous peptide does not have a tertiary structure in isolation. In some embodiments, the
- heterologous peptide does not have a biological function.
- the heterologous peptide is synthetically designed, and is not derived from a naturally occurring peptide.
- the second heterologous peptide (P2) is about 5, 6, 7, 8, 9,
- the second heterologous peptide (P2) comprises about 50 or fewer, about 45 or fewer, about 40 or fewer, about 35 or fewer, about 30 or fewer, about 25 or fewer, about 20 or fewer, about 15 or fewer, or about 10 or fewer amino acids in length.
- the second heterologous peptide (P2) is about 5 to about 20 amino acid residues in length, such as about 5 to about 10, about 10 to about 15, or about 15 to about 20 amino acid residues in length.
- the second heterologous peptide (P2) includes one or more glycine residues or one or more serine residues. In some embodiments, the second
- heterologous peptide includes an amino acid sequence of (GGGGS) q (SEQ ID NO: 34), wherein q is 1, 2, 3, 4 or more.
- the drug conjugation moiety can include 0, 1, 2, 3, 4, 5 or more albumins or albumin fragments, which may be the same or different, and 1, 2, 3, 4, 5, or more heterologous peptides comprising a cysteine residue.
- the components of the drug conjugation moiety i.e., the one or more albumin or albumin fragments, if present, the one or more heterologous peptides comprising a cysteine residue, and the second heterologous peptide (P2) if present
- P2 second heterologous peptide
- the components of the drug conjugation moiety can be fused in any order, but are preferably fused such that at least one heterologous peptide is included between each albumin or albumin fragment when more than one albumins or albumin fragments are present.
- the antibody fusion molecule can include a polypeptide configured, from N-terminus to C-terminus, according to any of the following configurations:
- HL is the antibody heavy chain or the antibody light chain, or the fragment thereof;
- Pl, P2, P3, P4, and P5 are heterologous peptides; and A is an albumin or a fragment thereof.
- at least one or more of Pl, P3, P4, and P5 include a cysteine residue.
- each of Pl, P3, P4, and P5 include a cysteine residue.
- the second heterologous peptide (P2) includes a cysteine residue, and in some embodiments the second heterologous peptide (P2) does not include a cysteine residue.
- the antibody fusion molecule can include more than one drug conjugation moieties.
- the antigen fusion molecule includes a first drug conjugation moiety and a second drug conjugation moiety, wherein the first drug conjugation moiety is fused to the antibody heavy chain (or fragment) and the second drug conjugation moiety is fused to the antibody light chain (or fragment).
- the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
- the antibody fusion molecule can include two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody heavy chain (or fragment), and a second drug conjugation moiety is fused to a second antibody heavy chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
- the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody light chain (or fragment), and a second drug conjugation moiety is fused to a second antibody light chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
- the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to one of the antibody heavy chains (or fragments), and a second drug conjugation moiety is fused to one of the antibody light chains (or fragments), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
- the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody light chain (or fragment), a second drug conjugation moiety is fused to a second antibody light chain (or fragment), a third drug conjugation moiety is fused to a first antibody heavy chain (or fragment), and a fourth drug conjugation moiety is fused to a second antibody heavy chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), wherein the heterologous peptide comprises a cysteine residue.
- Pl is charged.
- the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof.
- the drug conjugation moiety is fused to the antibody light chain or fragment thereof.
- the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof.
- the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- Pl first heterologous peptide
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof.
- the drug conjugation moiety is fused to the antibody light chain or fragment thereof.
- the antigen-binding moiety comprises a full length antibody.
- the antigen-binding moiety comprises an antibody fragment.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- Pl a first heterologous peptide
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- Pl first heterologous peptide
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments,
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- Amino acid residues 1-19 of SEQ ID NO: 32 are a signal peptide, which is optionally excluded from the antibody fusion molecule.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1072 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1072 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments,
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33.
- the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33.
- the polypeptide comprising residues465-l075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO:
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- Amino acid residues 1-19 of SEQ ID NO: 32 are a signal peptide, which is optionally excluded from the antibody fusion molecule.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1075 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1075 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- a polypeptide or a drug conjugation moiety comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of Pl.
- Pl is charged.
- Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- a polypeptide or a drug conjugation moiety comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- polypeptide or a drug conjugation moiety that comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1072 of SEQ ID NO: 32.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1072 of SEQ ID NO: 32.
- the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 480-1072 of SEQ ID NO: 32.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 480- 1072 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1064 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1064 of SEQ ID NO: 32.
- polypeptide or drug conjugation moiety that comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 483-1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 483- 1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1067 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1067 of SEQ ID NO: 33.
- the antibody fusion molecules described herein can further include a payload molecule, such as a drug molecule, covalently bound to the cysteine residue in any one or more of the heterologous peptides through a conjugation linker.
- a payload molecule such as a drug molecule
- the number of payload molecules attached to the antibody fusion molecule can be determined based on the number of heterologous peptides comprising cysteines, and the number of drug molecules that are conjugated to each cysteine.
- the payload molecule can be a hydrophobic payload molecule, such as a hydrophobic drug molecule.
- the payload molecule has a solubility of about 10 mg/mL or less, about 5 mg/mL or less, about 2.5 mg/mL or less, about 1 mg/mL or less, about 0.5 mg/mL or less, about 0.2 mg/mL or less, about 0.1 mg/mL or less, about 0.005 mg/mL or less, about 0.02 mg/mL or less, or about 0.01 mg/mL or less) in water at pH 7 at 25 °C.
- the payload molecule is a drug molecule. In some embodiments, the payload molecule is a drug molecule.
- the drug molecule is a cytotoxic drug, an anti-viral drug, or an anti-bacterial drug.
- exemplary drugs that can be conjugated to the antibody fusion molecule includes an antibiotic, a microtubule disrupting agent, a DNA modifying agent, an RNA polymerase inhibitor, or a topoisomerase I inhibitor.
- the drug is azaribine, anastrozole, azacitidine, bleomycin, bortezomib, bryostatin-l, busulfan, camptothecin, 10- hydroxycamptothecin, calicheamicin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol, doxorubicin, doxorubicin glucuronide, duocarmycin, duomycin, epirubicin, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, floxuridine, fludarabine, flutamide,
- the payload molecule is an imaging agent, such as a fluorescent imaging agent or an MRI contrast agent.
- the antibody fusion molecule includes one or more payload molecules, such as 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more payload molecules.
- the antibody fusion molecule includes 2 to 30 payload molecules, such as 2 to 4, 4 to 8, 8 to 12, 12 to 16, 16 to 20, 20 to 25, or 25 to 30 payload molecules.
- the payload molecule can be conjugated to the cysteine on the heterologous peptide through any suitable conjugation linkers.
- the payload molecule is conjugated to the cysteine through a maleimide moiety (i.e., through maleimide alkylation) or through cysteine arylation (e.g., through the use of a palladium complex).
- the maleimide moiety is a N-alkyl maleimide moiety. Binding of the maleimide moiety to the thiol of the cysteine results in a succinimide thioether, which can be hydrolyzed into a ring-opened counterpart.
- the conjugation linker is not cleavable.
- Payload molecules, such as drug molecules, conjugated to the antibody fusion molecule through a non-cleavable linker are leased after the antibody fusion molecule is internalized by the target cell and the polypeptide components of the antibody fusion molecule are degraded by the lysosome.
- the conjugation linker is a cleavable linker.
- cleavable linkers may include a pH- sensitive cleavable linker (such as a linker with a hydrazine moiety which is cleavable in acidic conditions), an enzymatically cleavable linker, such as a linker with a protease-cleavable moiety (such as a valine-alanine (Val-Ala) dipeptide component or a valine-citrulline dipeptide component, which may be
- a pH- sensitive cleavable linker such as a linker with a hydrazine moiety which is cleavable in acidic conditions
- an enzymatically cleavable linker such as a linker with a protease-cleavable moiety (such as a valine-alanine (Val-Ala) dipeptide component or a valine-citrulline dipeptide component, which
- linker cleavable under reducing conditions such as a linker having a disulfide bond, which is cleavable in intracellular reducing conditions
- linker cleavable under reducing conditions such as a linker having a disulfide bond, which is cleavable in intracellular reducing conditions
- exemplary conjugation linkers for conjugating the drug to a cysteine in the heterologous peptide are discussed in Tsuchikama et ah, Antibody-drug conjugates: recent advances in conjugation and linker chemistries, Protein & Cell, vol. 9, pp. 33-46 (2016), first available online Oct. 14, 2016.
- z is 4-24; and the maleimide group is covalently attached to the cysteine of the heterologous peptide through the maleimide group.
- the conjugation linker conjugated to the cysteine of the heterologous peptide is bound to two or more payload molecules.
- the two or more payload molecules may optionally be independently cleavable from the conjugation linker, for example by including a cleavable bond for each payload molecule.
- an antibody fusion molecule comprising antigen binding moiety that binds to DLL3, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl), wherein the heterologous peptide comprises a cysteine residue conjugated to a DNA- modifying agent.
- the DNA-modifying agent is pyrrolobenzodiazepine (PBD), a PBD dimer, calicheamicin, duomycin, or duocarmycin.
- the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
- an antibody fusion molecule comprising antigen binding moiety that binds to Trop-2, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl), wherein the heterologous peptide comprises a cysteine residue conjugated to a topoisomerase inhibitor.
- the topoisomerase inhibitor is SN-38.
- the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
- an antibody fusion molecule comprising antigen binding moiety that binds to Claudin 18.2, but not to Claudin 18.1, or binds to Claudin 18.1 with at least 10 times weaker binding affinity than to Claudin 18.2, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) , wherein the heterologous peptide comprises a cysteine residue conjugated to a DNA-modifying agent, a microtubule disrupting agent, or a topoisomerase inhibitor.
- Pl heterologous peptide
- the cysteine residue is conjugated to monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), SN-38, PBD, a PBD dimer, calicheamicin, duomycin, or duocarmycin.
- the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), wherein the heterologous peptide comprises a cysteine residue conjugated to a payload molecule (such as a drug molecule, for example a cytotoxic drug molecule).
- Pl is charged.
- the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof.
- the drug conjugation moiety is fused to the antibody light chain or fragment thereof.
- the antigen-binding moiety comprises a full length antibody.
- the antigen-binding moiety comprises an antibody fragment.
- Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl.
- a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- a cysteine residue conjugated to a payload molecule such as a drug molecule (such as a cytotoxic drug molecule)
- an albumin or an albumin fragment fused to Pl such as
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of Pl.
- the drug conjugation moiety is fused to the antigen-binding moiety via Pl.
- the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment.
- Pl is charged.
- the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl.
- a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- a cysteine residue conjugated to a payload molecule such as a drug molecule (such as a cytotoxic drug molecule)
- an albumin or an albumin fragment fused to Pl such as a drug molecule (
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of Pl.
- the drug conjugation moiety is fused to the antigen -binding moiety via Pl.
- the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment.
- Pl is charged.
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl.
- a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- a cysteine residue conjugated to a payload molecule such as a drug molecule (such as a cytotoxic drug molecule)
- an albumin or an albumin fragment fused to Pl such as a drug molecule (
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of Pl.
- the drug conjugation moiety is fused to the antigen -binding moiety via Pl.
- the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment.
- Pl is charged.
- Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- a first heterologous peptide Pl
- a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof.
- the drug conjugation moiety is fused to the antibody light chain or fragment thereof.
- the antigen-binding moiety comprises a full length antibody.
- the antigen-binding moiety comprises an antibody fragment.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- a cysteine residue conjugated to a payload molecule such as a drug molecule (such as a cyto
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length)
- a cysteine residue conjugated to a payload molecule such as a drug molecule (such as a cyto
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl.
- the albumin or albumin fragment is fused to the C-terminus of P2.
- the drug conjugation moiety is fused to the antigen-binding moiety via P2.
- P2 does not comprise a cysteine.
- Pl is charged.
- Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments,
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- a payload molecule such as a drug molecule
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- a payload molecule such as a drug molecule
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment.
- the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments,
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1072 of SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments,
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprising an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1072 of SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 33, wherein a payload molecule is conjugated to the polypeptide.
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33.
- the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide.
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33.
- the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- a payload molecule such as a drug molecule
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment.
- the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide.
- a payload molecule such as a drug molecule
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment.
- the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1075 of SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide.
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33.
- the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
- the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1075 of SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide.
- the drug molecule is conjugated to Cys477 of SEQ ID NO: 33.
- the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
- the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
- polypeptide or drug conjugation moiety comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a drug molecule, and (2) an albumin or an albumin fragment fused to Pl.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- a polypeptide or drug conjugation moiety comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a drug molecule, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment.
- the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment.
- the albumin is a full length albumin.
- the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
- polypeptide or drug conjugation moiety comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 480- 1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 480-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465- 1064 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1064 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule.
- the drug molecule is conjugated to Cysl070 of SEQ ID NO: 32.
- polypeptide or drug conjugation moiety comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 483-1075 of SEQ ID NO: 33.
- the polypeptide or drug conjugation moiety comprises a sequence according to residues 483-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465- 1067 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1067 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
- compositions of the antibody fusion molecules and antibody fusion molecule drug conjugates are prepared by mixing the antibody fusion molecules or the antibody fusion molecule drug conjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (see Remington's Pharmaceutical Sciences l6th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
- Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
- hexamethonium chloride benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
- polypeptides such as serum albumin, gelatin, or immunoglobulins
- proteins such as serum albumin, gelatin, or immunoglobulins
- hydrophilic polymers such as polyvinylpyrrolidone
- amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine
- chelating agents such as EDTA
- sugars such as sucrose, mannitol, trehalose or sorbitol
- salt-forming counter-ions such as sodium
- metal complexes e.g. Zn-protein complexes
- non-ionic surfactants such as polyethylene glycol (PEG).
- Buffers are used to control the pH in a range which optimizes the therapeutic effectiveness, especially if stability is pH dependent. Buffers are preferably present at concentrations ranging from about 50 mM to about 250 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof, such as citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate. Additionally, buffers may comprise histidine and trimethylamine salts such as Tris.
- Preservatives are added to retard microbial growth, and are typically present in a range from 0.2% - 1.0% (w/v). Suitable preservatives for use with the present invention include octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
- benzalkonium halides e.g., chloride, bromide, iodide
- benzethonium chloride thimerosal, phenol, butyl or benzyl alcohol
- alkyl parabens such as methyl or propyl paraben
- catechol resorcinol
- cyclohexanol 3-pentanol, and m-cresol.
- Tonicity agents sometimes known as“stabilizers” are present to adjust or maintain the tonicity of liquid in a composition. When used with large, charged biomolecules such as proteins and antibodies, they are often termed“stabilizers” because they can interact with the charged groups of the amino acid side chains, thereby lessening the potential for inter- and intra-molecular interactions. Tonicity agents can be present in any amount between 0.1% to 25% by weight, or more preferably between 1% to 5% by weight, taking into account the relative amounts of the other ingredients.
- Preferred tonicity agents include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
- Non-ionic surfactants or detergents are present to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody.
- Non-ionic surfactants are present in a range of about 0.05 mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2 mg/ml.
- Suitable non-ionic surfactants include polysorbates (20, 40, 60, 65, 80, etc.), polyoxamers (184, 188, etc.), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose.
- Anionic detergents that can be used include sodium lauryl sulfate, dioctyle sodium sulfosuccinate and dioctyl sodium sulfonate.
- Cationic detergents include benzalkonium chloride or benzethonium chloride.
- compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) or solubilizing agent(s).
- compositions useful in the present invention may be formulated to be administered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route.
- the formulation may be designed to be administered by a number of routes.
- an antibody formulation is a lyophilized antibody formulation. In another embodiment, an antibody formulation is an aqueous antibody formulation.
- the antibody fusion molecule conjugated to a drug can be used to treat a disease, depending on the antigen bound by the antigen-binding domain and the drug conjugated to the heterologous peptide.
- the antibody fusion molecule drug conjugate is used to treat cancer, for example when the drug molecule is a cytotoxic agent.
- the antibody fusion molecule drug conjugate is used to treat an infection, for example when the drug molecule is an antibacterial agent or an antiviral agent.
- Other diseases that may be treated include metabolic diseases (such as diabetes), bone diseases (such as osteoporosis), obesity, heart disease, or liver disease.
- a method of treating a disease comprises administering to the subject an effective amount of an antibody fusion molecule conjugated to a cytotoxic drug through a cysteine of the heterologous peptide.
- the cancer is a solid cancer.
- the cancer is a blood cancer.
- Exemplary cancers that may be treated include, but are not limited to, leukemia, lymphoma, kidney cancer, bladder cancer, urinary tract cancer, cervical cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, esophageal cancer, liver cancer, colorectal cancer, stomach cancer, squamous cell carcinoma, prostate cancer, pancreatic cancer, lung cancer, cholangiocarcinoma, breast cancer, and ovarian cancer.
- the cancer has one or more mutant RAS family genes.
- the cancer cell has upregulated macropinocytosis compared to a non- cancerous cell.
- the antibody fusion molecule conjugated to a drug is used to treat a bacterial infection.
- the bacteria causing the bacterial infection is a drug-resistant bacteria.
- the antigen-binding moiety binds to a bacterial antigen.
- the drug conjugated to the antibody fusion molecule is an antibacterial agent.
- the antibody fusion molecule conjugated to a drug is used to treat a viral infection.
- the virus causing the viral infection is hepatitis C (HCV), hepatitis B (HBV), human immunodeficiency virus (HIV), a human papilloma virus (HPV).
- the antigen-binding moiety binds to a viral antigen.
- the drug conjugated to the antibody fusion molecule is an anti-viral agent.
- the antibody fusion molecule is administered to a subject through any route, including orally, transdermally, by inhalation, intravenously, intra-arterially, intramuscularly, direct application to a wound site, application to a surgical site, intraperitoneally, by suppository, subcutaneously, intradermally, transcutaneously, by nebulization, intrapleurally, intraventricularly, intra-articularly, intraocularly, or intraspinally.
- the composition is administered to a subject intravenously.
- the dosage of the antibody fusion molecule conjugated to the drug is a single dose or a repeated dose.
- the doses are given to a subject once per day, twice per day, three times per day, or four or more times per day.
- about 1 or more (such as about 2, 3, 4, 5, 6, or 7 or more) doses are given in a week.
- the antibody fusion molecule conjugated to the drug is administered weekly, once every 2 weeks, once every 3 weeks, once every 4 weeks, weekly for two weeks out of 3 weeks, or weekly for 3 weeks out of 4 weeks.
- multiple doses are given over the course of days, weeks, months, or years.
- a course of treatment is about 1 or more doses (such as about 2, 2, 3, 4, 5, 7,
- Polypeptides that include an antibody heavy chain (or fragment) or an antibody light chain (or fragment) fused to a drug conjugation moiety can be produced using recombinant DNA methods.
- Nucleic acid molecules encoding the fusion polypeptide can be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid molecules may be readily isolated and sequenced using conventional methods.
- the antibody light chain or fragment or the variable heavy chain or fragment, wherein the antibody heavy chain or the antibody light chain is fused to the drug conjugation moiety may be co-expressed in the same host cell.
- Suitable host cells for cloning or expression of fusion polypeptide vectors include prokaryotic cells or eukaryotic cells. Exemplary host cells include Chinese Hamster Ovary (CHO) cells or human embryonic kidney cells (e.g.,
- Expression host cells express the antibody fusion molecule. After an expression period, the host cells can by lysed and the antibody fusion molecule purified. Exemplary purification methods include liquid chromatography, such as ion exchange chromatography, affinity chromatography (such as Protein A affinity chromatography), or size exclusion chromatography.
- Drug molecules can be attached to a conjugation linker, for example during synthesis of the drug molecule or through a conjugation chemistry.
- the linker can include, for example, a maleimide moiety, which can react with a thiol group.
- the drug attached to the conjugation linker can be combined with the purified antibody fusion molecule, such that the drug molecule conjugates to a cysteine of one of the heterologous peptides comprising a cysteine.
- the maleimide moiety reacts with the cysteine residue in the heterologous peptide to form a succinimide thioether.
- the ring in the succinimide thioether can open after hydrolysis, thereby forming a stable conjugation between the heterologous peptide and the drug.
- the conjugation linker is conjugated to the antibody fusion molecule prior to attaching the conjugation linker to the drug.
- the drug can be conjugated to the antibody fusion molecule by mixing the antibody fusion molecule and the drug in solution.
- the drug is generally mixed with the antibody fusion molecule in molar excess (that is, a molar ratio of drug to antibody fusion molecule of about 1 or more).
- the molar ratio of drug to antibody fusion molecule is about 1 to about 1 or more, about 2 or more, about 3 or more, about 4 or more, about 5 or more, about 6 or more, about 7 or more, or about 8 or more.
- the molar ratio of drug to antibody fusion molecule is about 1 to about 20, about 2 to about 15, about 4 to about 10, or about 6 to about 8.
- the antibody fusion molecule can be conjugated to the drug with or without mixing the antibody fusion molecule with a reducing agent.
- exemplary reducing agents that may be used include tris (2-carboxyethyl)phosphine (TCEP), b-mercaptoethanol (B-ME) and dithiothreitol (DTT).
- TCEP 2,-carboxyethyl)phosphine
- B-ME b-mercaptoethanol
- DTT dithiothreitol
- the reducing agent can be mixed with the antibody fusion molecule to reduce thiolates on the protein prior to conjugating the drug to the antibody fusion molecule.
- the reducing agent may be mixed with the antibody fusion molecule at a molar ratio
- the reducing agent is mixed with the antibody fusion molecule at a molar ratio (reducing agent to antibody fusion molecule) of about 1 to about 100, about 2 to about 75, about 5 to about 50, about 10 to about 40, or about 20 to about 30. In some embodiments, the reducing agent is removed from the composition containing the antibody fusion molecule prior to conjugating the drug to the antibody fusion molecule.
- the antibody fusion molecule is optionally treated with an oxidizing agent prior to conjugating the antibody fusion molecule with the drug.
- oxidizing agents can include ascorbic acid, cysteine, oxidized glutathione, and copper ions.
- the antibody fusion molecule can be further purified, for example to isolate the antibody fusion molecule conjugated to the drug from unreacted polypeptides, unreacted drug molecules, or antibody fusion molecules that are over- or under- conjugated to the drug molecules.
- Exemplary purification methods include liquid chromatography, such as ion exchange chromatography, affinity chromatography (such as Protein A affinity chromatography), or size exclusion chromatography. The purification methods can be used to isolate antibody drug conjugate molecules with a uniform drug-antibody ratio (DAR).
- DAR drug-antibody ratio
- Expression plasmid constructs containing DNA sequences encoding the genes of the GPC3 antibody light chain (SEQ ID NO: 14) and antibody heavy chain-albumin fusion protein (SEQ ID NO: 33) were transfected into HEK-293 cells using polyethylenimine (PEI) for transient expression.
- the transfected cells were treated with valproic acid (VPA) 24 hours post transfection to enhance protein expression.
- the supernatants were harvested on day 6 and the antibodies were purified.
- the antibody- albumin fusion protein was first captured by a Protein A affinity column, and eluted using a 0.5 M arginine buffer, pH 3.8. The pH of the eluted antibody- albumin fusion protein was adjusted to ⁇ 5.6, and the pH-adjusted elute was filtered. The antibody fusion protein was further purified by an anion exchange chromatography using Capto Q Impres resin. The purified antibody- albumin fusion protein was the formulated in a formulation containing 12 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7. It was stored at 2-8 °C or -80 °C until use.
- Example 2 Drug Conjugation to Antibody- Albumin Fusion Protein
- Example 1 The antibody- albumin fusion protein expressed and purified as described in Example 1 was conjugated to MC-vc-PAB-MMAE (FIG. 1) according to the methods described in Reactions A-E, below.
- Reaction A The antibody- albumin fusion protein expressed and purified as described in Example 1 was conjugated to MC-vc-PAB-MMAE in the fusion protein storage buffer (2 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7). The resulting antibody solution was adjusted to a concentration of >3 mg/mL. The presence of free, accessible thiols for cysteine- maleimide conjugation was measured using a standard Ellman’s reagent assay (ThermoFisher Scientific, Catalog # 22582). Briefly, Ellman’s reagent stock solution was prepared in DMSO at 0.1M before 1: 100 dilution into conjugation buffer.
- Solid MC-vc-PAB-MMAE drug-linker reagent (Levena Biopharma U.S.) was first dissolved in DMSO at 5 mM concentration before being added in 4-8-fold molar excess to the PG-containing antibody solution. After thorough mixing, the resulting conjugation reaction was allowed to incubate at room temperature for a minimum of 1.5 h.
- Reaction progress was monitored via hydrophobic interaction chromatography (HIC) on an Agilent 1100 HPLC system using a MAbPacTM HIC- 10 column (5 pm particles, 1000 A pore size, 4.6 x 100 mm column, ThermoFisher Scientific, Catalog # 088480).
- the column temperature was set to 30 °C and a flow rate was set at 1 mL/min.
- the column was loaded with approximately 50-100 pg protein for analysis, and the column elute was monitored with by UV at wavelengths of 280 nm and 252 nm.
- FIG. 2 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction A.
- the A280 peaks indicating conjugate formation were measured relative to unmodified antibody and drug-linker control injections. Average DAR (drug-to-antibody ratio) and % unmodified antibody-albumin fusion protein were determined via A280 peak area integration. The drug-antibody ratio (DAR) was calculated using the following equitation:
- Reaction B The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)). The antibody- albumin fusion protein was conjugated to MC-vc-PAB-MMAE in the conjugation buffer as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A.
- FIG. 3 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction B.
- Reaction C The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)) before being partially reduced using 2.5x molar ratio of the reducing reagent tris(2-carboxyethyl)phosphine (TCEP).
- the conjugation reaction was conducted using 8x of MC-vc-PAB-MMAE at room temperature for
- FIG. 4 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction C.
- Reaction D The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)) before being reduced using 20x molar ratio of the reducing reagent TCEP.
- conjugation buffer 50 mM sodium phosphate, 4 mM EDTA, pH 7.0
- centrifugal ultrafiltration using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)
- the antibody-albumin fusion protein was then incubated with TCEP for 48 hours at 2-8 °C to fully reduce the antibody- albumin fusion protein.
- the TECP was removed and free thiol content was measured.
- FIG. 5 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction D.
- Reaction E Reaction D.
- the antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra-4 10 KDa centrifugal filter units (Millipore Sigma)) before being reduced using 20x molar ratio of the reducing reagent TCEP.
- the antibody- albumin fusion protein was then incubated with TCEP for 48 hours at 2-8 °C to fully reduce the antibody- albumin fusion protein.
- the antibody-albumin fusion protein was then partially re-oxidized using ascorbic acid at room temperature for 1 hour.
- the conjugation reaction was conducted using 8x of MC-vc-PAB-MMAE at room temperature for approximately 1 hour, as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A.
- FIG. 6 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction E.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Described herein are novel antibody-drug conjugates (ADC), including antibody-albumin-drug conjugates (AADC). Further included in the present application are methods of using the novel antibody-drug conjugates and antibody-albumin-drug conjugates. The antibody fusion molecule can include an antigen binding moiety having an antibody heavy chain or fragment, and an antibody light chain or fragment. The antigen binding moiety is fused to a drug conjugation moiety, which includes a heterologous peptide having a cysteine and, optionally, an albumin or an albumin fragment. A payload, such as a drug molecule, can be conjugated to the cysteine residue on the heterologous peptide.
Description
NOVEL ANTIBODY-DRUG CONJUGATES (ADC), METHODS OF MAKING, AND
METHODS OF USE THEREOF
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority benefit to U.S. Provisional Patent Application No. 62/625,709, entitled“NOVEL ANTIBODY-DRUG CONJUGATES (ADC) AND
METHODS OF USE THEREOF,” filed February 2, 2018, the entire contents of which are incorporated herein by reference.
SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE
[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 737252000l40SEQLIST.TXT, date recorded: February 1, 2019, size: 80 KB).
FIELD OF THE INVENTION
[0003] The present application relates to novel antibody-drug conjugates (ADC), including antibody-albumin-drug conjugates (AADC). Further included in the present application are methods of using the novel antibody-drug conjugates and antibody-albumin-drug conjugates
BACKGROUND
[0004] Antibody-drug conjugates (ADC) allow for targeted delivery of a therapeutic agent, particularly to cancer cells, which can reduce side-effects commonly associated with chemotherapy. The antibody portion of the ADC can also allow for biological modulation that further enhances the efficacy of the conjugated drug. The drug molecule is generally conjugated through a cleavable or non-cleavable linker that attaches to a cysteine or lysine on the antibody molecule. The drug to antibody ration (DAR) of the ADC is limited, in part, by the number of moieties within the antibody that the drug can be linked to and the
hydrophobicity of the drug. Most ADCs having an average DAR between 0 and 8. Higher DAR of the complex allows for more potent ADC for use as therapeutics.
[0005] Additionally, most ADC molecules in clinical trials have half-lives of about 7 days or shorter (Deslandes, Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies , MAbs, vol. 6, no. 4, pp. 859-870 (2014)), which is
significantly shorter than most non-conjugated antibodies. Hydrophobicity of the ADC molecules due to the conjugated drugs is believed to be a significant contribution to the diminished stability, particularly in vivo , Lyon et al., Reducing hydrophobicity of
homogenous antibody-drug conjugates improvise pharmacokinetics and therapeutic index , Nature Biotechnology, vol. 33, pp. 733-7355 (2015).
[0006] The disclosures of all publications, patents, and patent applications referred to herein are each hereby incorporated herein by reference in their entireties.
SUMMARY OF THE INVENTION
[0007] Described herein are antibody fusion molecules, including antibody fusion molecules conjugated to a payload molecule, such as a drug molecule (e.g., a cytotoxic drug molecule). Also described are methods of making such antibody fusion molecules and methods of treating a disease in a subject comprising administering an effective amount of the antibody fusion molecule to the subject.
[0008] The antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain and an antibody light chain, or a fragment thereof, and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof wherein the drug conjugation moiety comprises a heterologous peptide (Pl) less than about 50 amino acids in length, and wherein Pl comprises a cysteine residue. In some embodiments, the heterologous peptide (Pl) is about 5 to about 20 amino acids in length.
[0009] In some embodiments, the antigen-binding moiety binds to one or more antigen on a surface of a cancer cell. In some embodiments, the cancer cell has upregulated
macropinocytosis. In some embodiments, the cancer cell comprises one or more mutant RAS family genes.
[0010] In some embodiments, the heterologous peptide (Pl) is unstructured or is helical.
[0011] In some embodiments, the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody heavy chain, or the fragment thereof. In some embodiments, the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody light chain, or the fragment thereof.
[0012] In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment.
[0013] In some embodiments, the drug conjugation moiety comprises an albumin, or an albumin fragment, fused to Pl. In some embodiments, the cysteine residue of Pl is about 30
amino acid residues or less away from a first residue a last residue of the albumin or the albumin fragment. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the albumin or the albumin fragment. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via Pl. In some
embodiments, the albumin or the albumin fragment has a point mutation at Cys34. In some embodiments, the point mutation is Cys34Ser. In some embodiments, the drug conjugation moiety comprises a full length albumin. In some embodiments, the drug conjugation moiety comprises the albumin fragment. In some embodiments, the albumin has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.
[0014] In some embodiments, the drug conjugation moiety comprises a second heterologous peptide (P2), which is fused to the albumin or albumin fragment. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the second heterologous peptide (P2). In some embodiments, the second heterologous peptide (P2) comprises a cysteine residue. In some embodiments, the second heterologous peptide (P2) does not comprise a cysteine residue. In some embodiments, the second heterologous peptide (P2) is helical or unstructured. In some embodiments, the second heterologous peptide (P2) is about 5 to about 20 amino acid residues in length. In some embodiments, the second heterologous peptide (P2) comprises one or more glycine residues or one or more serine residues. In some embodiments, the second heterologous peptide (P2) comprises an amino acid sequence of (GGGGS)q (SEQ ID NO: 34), wherein q is 1 or more.
In some embodiments, the second heterologous peptide (P2) comprises an amino acid sequence of (GGGGS)q (SEQ ID NO: 34), wherein q is 1, 2, 3, or 4.
[0015] In some embodiments, the drug conjugation moiety comprises two or more albumins or albumin fragments. In some embodiments, the drug conjugation moiety comprises three or more heterologous peptides. In some embodiments, each of the heterologous peptides comprises a cysteine residue.
[0016] In some embodiments, the antibody fusion molecules comprising a polypeptide configured, from N-terminus to C-terminus, according to:
HL-P1;
HL-P1-A
HL-P1-A-P3;
HL-P1-A-P3-A;
HL-P 1 - A-P3 - A-P4 ;
HL-P 1 - A-P3 - A-P4- A;
HL-P 1 - A-P3 - A-P4- A-P5 ;
HL-P2-A-P1;
HL-P2-A-P1-A;
HL-P2- A-P 1 - A-P3 ;
HL-P2- A-P 1 - A-P3 - A; or
HL-P2- A-P 1 - A-P3 - A-P4 ;
wherein HL is the antibody heavy chain or the antibody light chain, or the fragment thereof; wherein Pl, P3, P4, and P5 are heterologous peptides, wherein at least one of Pl, P3, P4, and P5 comprises a cysteine residue; wherein P2 is a heterologous peptide; and wherein A is an albumin or a fragment thereof.
[0017] In some embodiments, each of Pl, P3, P4, and P5 is about 5 to about 20 amino acid residues in length, and Pl, P3, P4, and P5 are of the same length or of different lengths. In some embodiments, at least one of Pl, P3, P4, and P5 comprises at least one charged amino acid. In some embodiments, at least one of Pl, P3, P4, and P5 comprises one or more positively charged amino acid residues. In some embodiments, the one or more positively charged amino acid residues are selected from the group consisting of lysine, histidine, arginine, and combinations thereof. In some embodiments, at least one of Pl, P3, P4, and P5 comprises one or more negatively charged amino acid residues. In some embodiments, the one or more negatively charged amino acid residues are selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
[0018] In some embodiments, at least one of Pl, P3, P4, and P5 comprises a sequence according to:
(GGGGS)nCXaa1Xaa2Xaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 35);
(GGGGS)nXaa1CXaa2Xaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 36);
(GGGGS)nXaa1Xaa2CXaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 37);
(GGGGS)„XaaiXaa2Xaa3CXaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 38);
(GGGGS)„XaaiXaa2Xaa3Xaa4CXaa5Xaa6(GGGGS)m (SEQ ID NO: 39);
(GGGGS)nXaa1Xaa2Xaa3Xaa4Xaa5CXaa6(GGGGS)m (SEQ ID NO: 40); or
(GGGGS)nXaa1Xaa2Xaa3Xaa4Xaa5Xaa6C(GGGGS)m (SEQ ID NO: 41);
wherein Xaai, Xaa2, Xaa3, Xaa4, Xaas, and Xaa6 are each either (1) a single amino acid, or none; wherein Xaai, Xaa2, Xaa3, Xaa4, Xaas, and Xaa6 has a net positive charge or a net negative charge; wherein n = 0, 1, 2, 3, or 4; wherein m = 0, 1, 2, 3, or 4; and wherein the
sequence of Pl, P3, P4, and P5 may be the same or different. In some embodiments Xaai, Xaa2, Xaa3, Xaa4, Xaa3, and Xaa6 comprise at least one positively charged amino acid residue and no negatively charged amino acid residues; or at least one negatively charged amino acid residue and no positively charged amino acid residues. In some embodiments, Xaai, Xaa2, Xaa3, Xaa4, Xaa3, and Xaa6 are each either (1) selected from the group consisting of histidine, lysine, arginine, aspartic acid, glutamic acid, glycine, serine, and threonine; or (2) none.
[0019] In some embodiments, the antibody fusion molecule comprises a full length antibody heavy chain or a full length antibody light chain.
[0020] In some embodiments, the antibody fusion molecule comprises a first drug
conjugation moiety fused to the antibody light chain, and a second drug conjugation moiety fused to the antibody heavy chain.
[0021] In some embodiments, the antibody fusion molecule comprises a first drug
conjugation moiety fused to a first antibody heavy chain, and a second drug conjugation moiety fused to a second antibody heavy chain, and wherein the first drug conjugation moiety and the second drug conjugation moiety are the same or different.
[0022] In some embodiments, the antibody fusion molecule comprises a first drug
conjugation moiety fused to a first antibody light chain, and a second drug conjugation moiety fused to a second antibody light chain, and wherein the first drug conjugation moiety and the second drug conjugation moiety are the same or different.
[0023] In some embodiments, the antibody fusion molecule further comprises a payload molecule covalently bound to the cysteine residue in any one or more of Pl, P3, P4, and P5.
In some embodiments, the payload molecule is covalently bound to the cysteine residue in Pl, P3, P4, or P5 through a conjugation linker.
[0024] In some embodiments, the payload molecule is a drug molecule. In some
embodiments, the drug molecule is a cytotoxic drug molecule. In some embodiments, the drug molecule is an anti- viral agent or an anti-bacterial agent. In some embodiments, the payload molecule is an imaging agent.
[0025] In some embodiments, the antibody fusion molecule comprises 2-30 payload molecules.
[0026] In some embodiments, the conjugation linker binds to the cysteine in Pl, P3, P4, or P5 through a maleimide moiety. In some embodiments, the maleimide moiety is a N-alkyl maleimide moiety.
[0027] In some embodiments, the conjugation linker is bound to two or more payload molecules.
[0028] In some embodiments, the drug molecule is a microtubule disrupting agent, a DNA modifying agents, an RNA polymerase inhibitors, or a topoisomerase I inhibitor.
[0029] In some embodiments, the conjugation linker is not cleavable. In some embodiments, the conjugation linker is cleavable.
[0030] In some embodiments, the conjugation linker comprises amino acids valine-alanine or valine-citrulline. In some embodiments, the conjugation linker and drug has a structure of:
wherein z is 4-24; and wherein the maleimide group is covalently attached to the cysteine in any one of Pl, P3, P4, or P5 through the maleimide group.
[0031] In some embodiments, binding of the conjugation linker to the cysteine residue in Pl, P3, P4, or P5 results in a ring-opened counterpart of a hydrolyzed succinimide thioether formed by maleimide-thiol conjugation.
[0032] Also provided herein is a pharmaceutical composition comprising any of the antibody fusion molecules described above, and a pharmaceutically acceptable excipient. Also provided herein is a method of treating a cancer in a subject, comprising administering to the subject with cancer an effective amount of the pharmaceutical composition, wherein the payload molecule is a cytotoxic drug. In some embodiments, the cancer expresses an antigen targeted by the antibody or fragment thereof, and comprises a mutant RAS gene.
[0033] Also provided herein is a method of making an antibody fusion molecule, comprising conjugating a payload molecule to the antibody fusion molecule as described above. In some embodiments, the payload molecule is conjugated to cysteine residue in Pl, P3, P4, or P5 through a conjugation linker. In some embodiments, the conjugation linker is conjugated to the payload molecule prior to conjugating the conjugation linker to the cysteine residue in Pl, P3, P4, or P5. In some embodiments, the conjugation linker is conjugated to the antibody fusion molecule prior to conjugating the conjugation linker to the drug molecule. In some embodiments, two or more drug molecules are conjugated to the conjugation linker. In some embodiments, the conjugation linker comprises a maleimide group. In some embodiments, the method comprises mixing the antibody fusion molecule with a reducing agent prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method
comprises removing the reducing agent prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method comprises mixing the antibody fusion molecule with an oxidizing agent after mixing the antibody fusion molecule with the reducing agent, and prior to conjugating the payload molecule to the fusion molecule. In some embodiments, the method comprises removing the oxidizing agent prior to conjugating the payload molecule to the fusion molecule.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 illustrates the chemical structure of an exemplary drug with conjugating linker, namely MC-vc-PAB-MMAE, which can be conjugated to an antibody fusion molecule.
[0035] FIG. 2 shows a hydrophobic interaction chromatography, high performance liquid chromatography (HIC-HPLC) chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC -vc-PAB-MMAE under storage buffer conditions (2 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7) (bottom panel).
[0036] FIG. 3 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) (bottom panel).
[0037] FIG. 4 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0 after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 2.5x molar ratio (TCEP to protein) (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 2.3.
[0038] FIG. 5 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 20x molar ratio (TCEP to protein) (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 3.3.
[0039] FIG. 6 shows a HIC-HPLC chromatogram for an expressed and purified antibody- albumin fusion protein (top panel) and the purified antibody- albumin fusion protein conjugated to MC-vc-PAB-MMAE under conjugation buffer conditions (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) after the antibody- albumin fusion protein was reduced with tris(2-carboxyethyl)phosphine (TCEP) at a 20x molar ratio (TCEP to protein), and then oxidized using ascorbic acid (bottom panel). Peaks were observed for antibody- albumin fusion protein conjugated to 0, 1, 2, 3, 4, and 5 molecules of MC-vc-PAB-MMAE, with an average DAR of 4.5.
DETAILED DESCRIPTION OF THE INVENTION
[0040] The present invention relates to compositions for targeted delivery of drug molecules. An antibody fusion molecule includes an antigen-binding moiety, which may include, for example, an antibody heavy chain and an antibody light chain, which binds to an antigen on a cell surface. Fused to the antigen-binding moiety or a polypeptide component of the antigen binding moiety, there is a drug conjugation moiety. The drug conjugation moiety includes a heterologous peptide that includes a cysteine residue, which can be conjugated to the drug. The antigen-binding moiety targets the drug to the cell by binding the antigen, which internalizes the antibody fusion molecule. Through this mechanism, the antibody fusion molecule can target the drug to the cell.
[0041] Optionally, the heterologous peptide of the drug conjugation moiety is fused to an albumin or an albumin fragment. The albumin or albumin fragment may be fused to the C-terminal end or the N-terminal end of the heterologous peptide. The albumin or the albumin fragment can bind the drug linked to the heterologous polypeptide, which enhances solubility of the drug. Accordingly, the antibody fusion molecule described herein is particularly beneficial for targeted delivery of hydrophobic payload molecules, such as drug molecules.
[0042] Some embodiments of the present invention include a drug conjugation moiety with a plurality of fused heterologous polypeptides, which allow the drug to antibody ratio to be increased by extending the number of heterologous polypeptides. Additionally, the drug conjugation moiety can optionally include a plurality of albumins or albumin fragments, which can enhance the solubility of the drugs molecules attached to the heterologous polypeptides. For example, an albumin or an albumin fragment can be included adjacent to each heterologous polypeptide to support the solubility of the drug molecule attached to that heterologous polypeptide. Although antibody-drug conjugates (ADCs) are known, the drug
molecules are generally conjugated directly to the antibody molecule. Such configuration limits the number of drug molecules that can be bound to the complex (that is, the drug to antibody ratio) due to the limited number of drug attachment sites on the antibody molecule. Additionally, attaching hydrophobic drugs to an antibody molecule can result in decreased solubility and stability of the complex.
[0043] Described herein is an antibody fusion molecule, comprising an antigen-binding moiety, and a drug conjugation moiety fused to the antigen-binding domain, wherein the drug conjugation moiety comprises a heterologous peptide (Pl), and wherein Pl comprises a cysteine residue. In some embodiments, Pl is less than about 50 amino acids in length. In some embodiments, the antigen-binding moiety includes an antibody heavy chain (or a fragment thereof) and an antibody light chain (or a fragment thereof), and the drug conjugation moiety is fused to the antibody heavy chain (or fragment thereof) or the antibody light chain (or fragment thereof). Also described are methods of making the antibody fusion molecule. The drug conjugation moiety can be fused to the N-terminus or the C-terminus of the antibody heavy chain or the antibody light chain. Optionally, the drug conjugation moiety includes an albumin or an albumin fragment, which is fused to Pl. In some embodiments, the drug conjugation moiety includes more than one heterologous peptides, which may be the same or different, or more than one albumins or albumin fragments.
[0044] The heterologous peptide includes a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or shorter. In some embodiments, a payload molecule, such as a cytotoxic drug molecule or any other drug molecule, is conjugated to the heterologous peptide, for example through the cysteine residue. In some embodiments, the antibody fusion molecule comprises 2 or more payload molecules. The payload molecule can be conjugated to the heterologous peptide through a cleavable or a non- cleavable linker.
[0045] Also described herein are methods of treating cancer in a subject by administering an effective amount of the antibody fusion molecule to the subject. The antibody fusion molecule can target an antigen on the surface of the cancer cells, thereby delivering the drug to the cancer. In certain embodiments, the cancer cell has upregulated micropinocytosis compared to a non-cancerous cell. For example, in some embodiments, the cancer has a RAS mutation, which has been linked to upregulated micropinocytosis.
[0046] It is understood that aspects and variations of the invention described herein include “consisting” and/or“consisting essentially of’ aspects and variations.
Definitions
[0047] As used herein and in the appended claims, the singular forms“a,”“or,” and“the” include plural referents unless the context clearly dictates otherwise.
[0048] Reference to“about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of“X.” Additionally, use of“about” preceding any series of numbers includes“about” each of the recited numbers in that series. For example, description referring to“about X, Y, or Z” is intended to describe“about X, about Y, or about Z.”
[0049] The term“antigen-binding moiety” refers to a polypeptide or a set of interacting polypeptides that specifically bind to an antigen, and includes, but is not limited to, an antibody or antibody fragment, such as a monoclonal antibody, polyclonal, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody (dAb), a diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding fragment thereof, bifunctional hybrid antibodies, a single chain antibody, and a Fc-containing polypeptide, such as an immunoadhesion. In some embodiments, the antibody may be of any heavy chain isotype (e.g., IgG, IgA, IgM, IgE, or IgD). In some embodiments, the antibody may be of any light chain isotype (e.g., kappa or gamma). The antibody may be non-human (e.g., from mouse, goat, or any other animal), fully human, humanized, or chimeric. In some embodiments, the antibody is a derivatized antibody.
[0050] The term“effective amount” used herein refers to an amount of a compound or composition sufficient to treat a specified disorder, condition, or disease, such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms. In reference to a disease such as a cancer, an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation in the cancer. In some embodiments, the effective amount is an amount sufficient to delay development of a cancer. In some embodiments, the effective amount is an amount sufficient to prevent or delay recurrence. An effective amount can be administered in one or more administrations. In the case of a cancer, the effective amount of the drug or composition may: (i) reduce the number of epithelioid cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop the cancer cells infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or
recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
[0051] The term“fused” or“fusion” in reference to two or more polypeptide sequences (such as an antibody heavy chain, antibody light chain, an antibody heavy chain fragment, an antibody light chain fragment, a drug conjugation moiety, a heterologous peptide, an albumin, or an albumin fragment) refers to joining of the polypeptide sequences through a backbone peptide bond.
[0052] The term“pharmaceutically acceptable” when used to refer to a compound or composition means that the compound or composition is suitable for administration to a subject, including a human subject, to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.
[0053] The term“subject” refers to a mammal and includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate.
[0054] As used herein,“treatment” or“treating” is an approach for obtaining beneficial or desired results including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms resulting from a disease, diminishing the extent of a disease, stabilizing a disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of a disease, preventing or delaying the recurrence of a disease, delaying or slowing the progression of a disease, ameliorating a disease state, providing remission (partial or total) of a disease, decreasing the dose of one or more other medications required to treat a disease, delaying the progression of a disease, increasing the quality of life, and/or prolonging survival. Also encompassed by“treatment” is a reduction of a pathological consequence of a disease (such as cancer). The methods of the invention contemplate any one or more of these aspects of treatment.
[0055] It is to be understood that one, some or all of the properties of the various
embodiments described herein may be combined to form other embodiments of the present invention.
[0056] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
Antibody Fusion Molecule
[0057] The antibody fusion molecule includes an antigen-binding moiety fused to a drug conjugation moiety. In some embodiments, the antigen-binding moiety includes an antibody heavy chain or a fragment thereof, and an antibody light chain or a fragment thereof. The drug conjugation moiety cam be fused to the antibody heavy chain or fragment thereof or the antibody light chain or fragment thereof. The drug conjugation moiety includes a
heterologous peptide (Pl), which includes a cysteine residue.
[0058] The antigen-binding moiety can be an antibody or a fragment thereof. For example, in some embodiments, the antigen binding moiety is a full length antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a disulfide linked Fv fragment, or a single chain variable fragment (scFv) fragment. In some embodiments, the antigen-binding moiety includes a full-length antibody heavy chain or a full-length antibody light chain. In some embodiments, the antigen-binding moiety includes an antibody heavy chain fragment or an antibody light chain fragment.
[0059] The antigen-binding moiety can bind an antigen on the surface of a cell, such as a cancer cell. In some embodiments, the antigen-binding moiety is a bispecific antigen-binging moiety, can bind to two different antigens or two different epitopes on the same antigen. In some embodiments, the antigen-binding moiety binds to Guanyl cyclase C (GCC), carbohydrate antigen 19-9 (CA19-9), glycoprotein A33 (gpA33), mucin 1 (MUC1), carcinoembryonic antigen (CEA), insulin-like growth factor 1 receptor (IGF1-R), human epidermal growth factor receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), delta-like protein 3 (DLL3), delta-like protein 4 (DLL4), epidermal growth factor receptor (EGFR), glypican-3 (GPC3), c-MET, vascular endothelial growth factor receptor 1 (VEGFR1) 1, vascular endothelial growth factor receptor 2 (VEGFR2), Nectin-4, Liv-l, glycoprotein NMB (GPNMB), pro state- specific membrane antigen (PSMA), Trop-2, carbonic anhydrase IX (CA9), endothelin B receptor (ETBR), Thomsen-Friedenrech antigen (TF), sodium-dependent phosphate transport protein 2B (NaPi2b), six transmembrane epithelial antigen of the prostate 1 (STEAP1), folate receptor alpha (FR-a), SLIT and NTRK- like protein 6 (SLITRK6), carbonic anhydrase VI (CA6), ectonucleotide
pyrophosphatase/phosphodiesterase family member 3 (ENPP3), mesothelin, trophoblast glycoprotein (TPBG), CD19, CD20, CD22, CD33, CD40, CD56, CD66e, CD70, CD74, CD79b, CD98, CD123, CD138, CD352, programmed death ligand 1 (PD-L1), Claudin 18.2, Claudin 6, or deacetylated b-1-6 polymer of N-acetyl glucosamine (dPNAG). In some embodiments, the antigen-binding moiety binds to an epidermal growth factor (EGF)-like
domain of DLL3. In some embodiments, the antigen-binding moiety binds to a Delta/S errate/Lag2 (DSL)-like domain of DLL3. In some embodiments, the antigen-binding moiety binds to an epitope located after the 374th amino acid of GPC3. In some
embodiments, the antigen-binding moiety binds to a heparin sulfate glycan of GPC3. In some embodiments, the antigen-binding moiety binds to Claudin 18.2 and does not bind to Claudin 18.1. In some embodiments, the antigen-binding moiety binds to Claudin 18.1 with at least 10 times weaker binding affinity than to Claudin 18.2
[0060] Exemplary antigen-binding moieties include trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, and fragments thereof. In some embodiments, the antigen-binding moiety that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to trastuzumab, rituximab, brentuximab, cetuximab, or panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof. In some embodiments, the antigen-binding moiety has an antibody heavy chain with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the antibody heavy chain of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof. In some embodiments, the antigen binding moiety has an antibody light chain with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the antibody light chain of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33 (or a humanized version thereof), anti-EGFR antibody mAb806 (or a humanized version thereof), anti-dPNAG antibody F598, or a fragment thereof. The antigen-binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a drug molecule is conjugated to the cysteine residue.
[0061] In some embodiments, the antigen-binding moiety comprises the six complementarity determining regions (CDRs) of trastuzumab, rituximab, brentuximab, cetuximab, panitumumab, GC33, anti-EGFR antibody mAb806, or anti-dPNAG antibody F598, A number of CDR delineations are known in the art and are encompassed herein. A person of skill in the art can readily determine a CDR for a given delineation based on the sequence of the heavy or light chain variable region. The“Rabat” Complementarity Determining
Regions (CDRs) are based on sequence variability and are the most commonly used (Rabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). “Chothia” CDRs refer to the location of the structural loops (Chothia & Lesk, Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., vol. 196, pp. 901-917 (1987)). The“AbM” CDRs represent a compromise between the Rabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software. The“Contact” CDRs are based on an analysis of the available complex crystal structures. The residues from each of these CDRs are noted below in Table 1, in reference to common antibody numbering schemes. Unless otherwise specified herein, amino acid number of antibodies refers to the Rabat numbering scheme as described in Rabat et al., supra, including when CDR delineations are made in reference to Rabat, Chothia, AbM, or Contact schemes. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a framework region (FR) or CDR of the variable domain. For example, a heavy-chain variable domain may include a single amino acid insert (residue 52a according to Rabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Rabat) after heavy-chain FR residue 82. The Rabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a“standard” Rabat numbered sequence.
Table 1: CDR Delineations According to Various Schemes
[0062] In some embodiments, the CDRs are“extended CDRs,” and encompass a region that begins or terminates according to a different scheme. For example, an extended CDR can be as follows: F24— F36, F26— F34, or F26— F36 (VF-CDR1); F46— F52, F46— F56, or F50— F55 (VF-CDR2); F91— F97 (VF-CDR3); H47— H55, H47— H65, H50— H55, H53— H58, or H53— H65 (VH-CDR2); and/or H93— H102 (VH-CDR3).
[0063] In some embodiments, the antigen-binding domain binds to HER2, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 2, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 3, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 2, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 3. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 2, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 3. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule is conjugated to the cysteine residue.
[0064] In some embodiments, the antigen-binding domain binds to CD20, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 4, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 5, or a fragment thereof. I n some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 4, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 5. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 4, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 5. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0065] In some embodiments, the antigen-binding domain binds to CD30, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 6, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 7, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 6, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 7. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 6, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 7. . The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0066] In some embodiments, the antigen-binding domain binds to EGF, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 8, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 9, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 8, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 9. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 8, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 9. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule is conjugated to the cysteine residue.
[0067] In some embodiments, the antigen-binding domain binds to EGFR, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 10 or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11 or a fragment thereof. I n some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 10, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 11. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 10, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 11. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0068] In some embodiments, the antigen-binding domain binds to c-MET, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 12, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 13. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 12, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 13. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0069] In some embodiments, the antigen-binding domain binds to GPC3, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 14 or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15 or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 15. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 15. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0070] In some embodiments, the antigen-binding domain binds to Claudin 18.2, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 16, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 17, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 16, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 17. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 16, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 17. The antigen-binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment.
In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0071] In some embodiments, the antigen-binding domain binds to dPNAG, and comprises a light chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18, or a fragment thereof, and a heavy chain having an amino acid sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19, or a fragment thereof. In some embodiments, the antigen-binding domain comprises an antibody light chain or an antibody light chain variable region comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 18, and an antibody heavy chain or an antibody heavy chain variable region comprising CDR1, CDR2, and CDR3 of the antibody heavy chain according to SEQ ID NO: 19. In some embodiments, the antigen-binding domain comprises the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 18, and the antibody heavy chain variable region of the antibody heavy chain according to SEQ ID NO: 19. The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0072] In some embodiments, the antigen-binding domain binds to Trop-2, and comprises a light chain variable region comprising a CDR1 comprising an amino acid sequence of KASQDVSIAVA (SEQ ID NO: 20), a CDR2 comprising an amino acid sequence of SASYRYT (SEQ ID NO: 21), and a CDR3 comprising an amino acid sequence of
QQHYITPLT (SEQ ID NO: 22); and a heavy chain variable region comprising a CDR1 comprising an amino acid sequence of NYGMN (SEQ ID NO: 23), a CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG (SEQ ID NO: 24), and a CDR3 comprising an amino acid sequence of GGFGSSYWYFDV (SEQ ID NO: 25). The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0073] In some embodiments, the antigen-binding domain binds to mesothelin, and comprises light chain variable region comprising a CDR1 comprising an amino acid sequence
of SASSSVSYMH (SEQ ID NO: 26), a CDR2 comprising an amino acid sequence of DTSKLAS (SEQ ID NO: 27), and a CDR3 comprising an amino acid sequence of
QQWSGYPLT (SEQ ID NO: 28); and a heavy chain variable region comprising a CDR1 comprising an amino acid sequence of GYTMN (SEQ ID NO: 29), a CDR2 comprising an amino acid sequence of LITP YN GAS S YN QKFRG (SEQ ID NO: 30), and a CDR3 comprising an amino acid sequence of GGYDGRGFDY (SEQ ID NO: 31). The antigen binding moiety is fused to a drug conjugation moiety comprising a heterologous peptide, wherein the heterologous peptide comprises a cysteine residue. In some embodiments, the heterologous peptide is about 50 amino acids in length or less. In some embodiments, the heterologous peptide is fused to an albumin or an albumin fragment. In some embodiments, a payload molecule, such as a drug molecule, is conjugated to the cysteine residue.
[0074] The drug conjugation moiety is a polypeptide that includes at least one heterologous peptide comprising a cysteine residue. In some embodiments, the drug conjugation moiety further includes one or more albumins or albumin fragment. The drug conjugation moiety is fused to the antibody heavy chain or the antibody light chain (or antibody heavy chain fragment or antibody light chain fragment) of the antigen fusion molecule, which may be at the N-terminus or the C-terminus of the antibody heavy chain (or fragment) or antibody light chain (or fragment).
[0075] In some embodiments, the heterologous peptide is unstructured. In some
embodiments, the heterologous peptide is helical. In some embodiments, the heterologous peptide does not have a tertiary structure in isolation. In some embodiments, the
heterologous peptide does not have a biological function. In some embodiments, the heterologous peptide is synthetically designed, and is not derived from a naturally occurring peptide. In some embodiments, the heterologous peptide is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid residues in length. In some embodiments, the heterologous peptide comprises about 50 or fewer, about 45 or fewer, about 40 or fewer, about 35 or fewer, about 30 or fewer, about 25 or fewer, about 20 or fewer, about 15 or fewer, or about 10 or fewer amino acids in length. In some embodiments, the heterologous peptide is about 5 to about 20 amino acid residues in length, such as about 5 to about 10, about 10 to about 15, or about 15 to about 20 amino acid residues in length. If the antibody fusion molecule includes two or more heterologous peptides, the heterologous peptides can be of the same length or of different lengths.
[0076] In some embodiments, the heterologous peptide includes at least one charged amino acid, which may be a positively charged amino acid or a negatively charged amino acid (as
determined at physiological pH). In some embodiments, the positively charged amino acid residue is lysine, histidine, or arginine. In some embodiments, the negatively charged amino acid residue is aspartic acid or glutamic acid. In some embodiments, the heterologous peptide has a net negative charge or a net positive charge.
[0077] The heterologous peptide can optionally include one or more (such as 1, 2, 3, or 4) GGGGS (SEQ ID NO: 42) sequences at the N-terminal end, the C-terminal end, or both the N-terminal end and the N-terminal end of the heterologous peptide. For example, in some embodiments, the heterologous peptide has the sequence:
(GGGGS)nXaalXaa2Xaa3Xaa4Xaa5Xaa6Xaa7(GGGGS)m, (SEQ ID NO: 43) wherein n is 0, 1, 2, 3, 4 or more, and wherein m is 0, 1, 2, 3, 4 or more. At least one of X^i, Xaa2. Xaa3, Xaa4, Xaa5. Xaa6, or Xaa7 is the cysteine reside included in the heterologous peptide. In some
embodiments, the Xaai, Xaa2, Xaa3, Xaa4, Xaa5, Xaa(„ and Xaa7 amino acid residues have a net positive charge or a net negative charge. In some embodiments, the Xaai, Xaa2, Xaa3, Xaa4, Xaa5, Xaaf , and Xaa7 amino acid residues include at least one positively charged amino acid residue and no negatively charged amino acid residues. In some embodiments, the X^i, Xaa2, Xaa3, Xaa4, Xaa5, Xaa(„ and Xaa7 amino acid residues include at least one negatively charged amino acid residue and no positively charged amino acid residues. In some embodiments, the Xaa amino acid residues are selected from histidine, lysine, arginine, aspartic acid, glutamic acid, glycine, serine, threonine, and combinations thereof. Although this example shows seven Xaa residues, in other embodiments, the heterologous peptide can include 1,2 ,3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19, 20 or more Xaa amino acid residues. Accordingly, in some embodiments, one or more of the Xaa amino acid residues are deleted, and in some embodiments, one or more additional Xaa amino acid residues are included between the (GGGGS)n (SEQ ID NO: 44) sequence and the (GGGGS)m (SEQ ID NO: 45) sequence.
[0078] In some embodiments, the drug conjugation moiety includes an albumin or a fragment thereof fused to the heterologous peptide. The albumin or fragment thereof can be fused to the N-terminal end or the C-terminal end of the heterologous peptide. The drug conjugation moiety can be fused to the antibody heavy chain (or fragment) or the antibody light chain (or fragment) via the albumin or albumin fragment or via the heterologous peptide. For example, the antibody fusion molecule can include a polypeptide having the configuration HL-A-P (wherein HL indicates the antibody heavy chain (or fragment) or antibody light chain (or fragment), A indicates the albumin (or fragment), and P indicates the heterologous peptide) or the configuration HL-P-A.
[0079] In some embodiments, the cysteine residue of the heterologous peptide is about 30,
25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residues or less from a first residue or a last residue of the albumin or the albumin fragment.
[0080] In some embodiments, the albumin is human albumin or a variant thereof. SEQ ID NO: 1 is the sequence of human albumin. In some embodiments, the albumin or albumin fragment is about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 99% or more, about 99.5% or more, or about 99.8% or more identical to human albumin or a fragment thereof.
[0081] In some embodiments, the drug conjugation moiety comprises a full length albumin. In some embodiments, the drug conjugation moiety comprises an albumin fragment that is about 10 or more, 20 or more, 30 or more 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 120 or more, 140 or more, 160 or more, 180 or more, 200 or more, 250 or more, 300 or more, 350 or more, 400 or more, 450 or more, 500 or more, or 550 or more amino acids in length. In some embodiments, the albumin fragment is between about 10 amino acids and about 584 amino acids in length (such as between about 10 and about 20, about 20 and about 40, about 40 and about 80, about 80 and about 160, about 160 and about 250, about 250 and about 350, about 350 and about 450, or about 450 and about 550 amino acids in length). In some embodiments, the albumin fragment includes the Sudlow I domain or a fragment thereof, or the Sudlow II domain or the fragment thereof.
[0082] In some embodiments, the albumin or albumin fragment includes one or more (such as 2, 3, 4, 5 or more) point mutations, amino acid insertions, or amino acid deletions.
Exemplary albumin variants are described in U.S. Patent Publication 2011/0313133. In some embodiments, the albumin or albumin fragment includes a point mutation at one or more cysteine residues. In some embodiments, the albumin or albumin fragment includes a point mutation at one or more of Dl, A2, C75, T79, E82, E86, C91, D121, C124, D129, C168, C169, C177, S270, C316, A364, C360, C361, C369, Q397, K500, A504, E505, D549, C558, D562, C567, K573, K574, A578, A581, or L585. In some embodiments, the albumin or albumin fragment includes a point mutation, insertion, or deletion adjacent to one or more of Dl, A2, C75, T79, E82, E86, C91, D121, C124, D129, C168, C169, C177, S270, C316,
A364, C360, C361, C369, Q397, K500, A504, E505, D549, C558, D562, C567, K573, K574, A578, A581, or L585. In some embodiments, the albumin or albumin fragment includes a point mutation at Cys34. In some embodiments, the albumin or albumin fragment includes a Cys34Ser point mutation.
[0083] Optionally, the drug conjugation moiety includes a second heterologous peptide in addition to one or more of the heterologous peptides described above. In some embodiments, the second heterologous peptide includes a cysteine residue. In some embodiments, the second heterologous peptide does not include a cysteine residue. The second heterologous peptide is fused to one of the other components of the drug conjugation moiety (i.e., an albumin or albumin fragment, and/or another heterologous peptide). For example, in some embodiments, the antibody fusion molecule includes a polypeptide having the configuration HL-P2-A-P1 (wherein HL indicates the antibody heavy chain (or fragment) or antibody light chain (or fragment), P2 indicates the second heterologous peptide that may or may not include a cysteine, A indicates the albumin (or fragment), and Pl indicates the heterologous peptide having a cysteine). In this configuration, the drug conjugation moiety is fused to the antibody heavy chain (or fragment) or the antibody light chain (or fragment) via the second heterologous peptide (P2), which is fused to the albumin or albumin fragment (A), which is fused to the first heterologous peptide (Pl).
[0084] In some embodiments, the second heterologous peptide (P2) is helical. In some embodiments, the second heterologous peptide (P2) is unstructured. In some embodiments, the second heterologous peptide (P2) is helical. In some embodiments, the heterologous peptide does not have a tertiary structure in isolation. In some embodiments, the
heterologous peptide does not have a biological function. In some embodiments, the heterologous peptide is synthetically designed, and is not derived from a naturally occurring peptide. In some embodiments, the second heterologous peptide (P2) is about 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid residues in length. In some embodiments, the second heterologous peptide (P2) comprises about 50 or fewer, about 45 or fewer, about 40 or fewer, about 35 or fewer, about 30 or fewer, about 25 or fewer, about 20 or fewer, about 15 or fewer, or about 10 or fewer amino acids in length. In some
embodiments, the second heterologous peptide (P2) is about 5 to about 20 amino acid residues in length, such as about 5 to about 10, about 10 to about 15, or about 15 to about 20 amino acid residues in length.
[0085] In some embodiments, the second heterologous peptide (P2) includes one or more glycine residues or one or more serine residues. In some embodiments, the second
heterologous peptide (P2) includes an amino acid sequence of (GGGGS)q (SEQ ID NO: 34), wherein q is 1, 2, 3, 4 or more.
[0086] The drug conjugation moiety can include 0, 1, 2, 3, 4, 5 or more albumins or albumin fragments, which may be the same or different, and 1, 2, 3, 4, 5, or more heterologous
peptides comprising a cysteine residue. The components of the drug conjugation moiety (i.e., the one or more albumin or albumin fragments, if present, the one or more heterologous peptides comprising a cysteine residue, and the second heterologous peptide (P2) if present) are fused together in a single polypeptide chain, which is fused to the antibody heavy chain (or fragment) or the antibody light chain (or fragment). The components of the drug conjugation moiety can be fused in any order, but are preferably fused such that at least one heterologous peptide is included between each albumin or albumin fragment when more than one albumins or albumin fragments are present.
[0087] By way of example, the antibody fusion molecule can include a polypeptide configured, from N-terminus to C-terminus, according to any of the following configurations:
HL-P1;
HL-P1-A
HL-P1-A-P3;
HL-P1-A-P3-A;
HL-P 1 - A-P3 - A-P4 ;
HL-P 1 - A-P3 - A-P4- A;
HL-P 1 - A-P3 - A-P4- A-P5 ;
HL-P2-A-P1;
HL-P2-A-P1-A;
HL-P2- A-P 1 - A-P3 ;
HL-P2- A-P 1 - A-P3 - A; or
HL-P2- A-P 1 - A-P3 - A-P4 ;
wherein HL is the antibody heavy chain or the antibody light chain, or the fragment thereof; Pl, P2, P3, P4, and P5 are heterologous peptides; and A is an albumin or a fragment thereof. In some embodiments, at least one or more of Pl, P3, P4, and P5 include a cysteine residue. In some embodiments, each of Pl, P3, P4, and P5 include a cysteine residue. In some embodiments, the second heterologous peptide (P2) includes a cysteine residue, and in some embodiments the second heterologous peptide (P2) does not include a cysteine residue.
[0088] The antibody fusion molecule can include more than one drug conjugation moieties. For example, in some embodiments, the antigen fusion molecule includes a first drug conjugation moiety and a second drug conjugation moiety, wherein the first drug conjugation moiety is fused to the antibody heavy chain (or fragment) and the second drug conjugation moiety is fused to the antibody light chain (or fragment). The first drug conjugation moiety and the second drug conjugation moiety may be the same or different. In another example,
the antibody fusion molecule can include two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody heavy chain (or fragment), and a second drug conjugation moiety is fused to a second antibody heavy chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different. In some embodiments, the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody light chain (or fragment), and a second drug conjugation moiety is fused to a second antibody light chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different. In some embodiments, the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to one of the antibody heavy chains (or fragments), and a second drug conjugation moiety is fused to one of the antibody light chains (or fragments), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different. In some embodiments, the antibody fusion molecule includes two antibody heavy chains (or fragments) and two antibody light chains (or fragments), and a first drug conjugation moiety is fused to a first antibody light chain (or fragment), a second drug conjugation moiety is fused to a second antibody light chain (or fragment), a third drug conjugation moiety is fused to a first antibody heavy chain (or fragment), and a fourth drug conjugation moiety is fused to a second antibody heavy chain (or fragment), wherein the first drug conjugation moiety and the second drug conjugation moiety may be the same or different.
[0089] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), wherein the heterologous peptide comprises a cysteine residue. In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment. In some
embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0090] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0091] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In
some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0092] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0093] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine.
In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0094] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0095] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some
embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0096] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 32. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0097] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0098] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues
465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0099] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0100] Amino acid residues 1-19 of SEQ ID NO: 32 are a signal peptide, which is optionally excluded from the antibody fusion molecule. Accordingly, in some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, or 99% identical to residues 20-1072 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0101] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1072 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0102] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 33. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0103] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule
comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0104] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0105] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues465-l075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO:
33 is fused to the antibody light chain or antibody light chain fragment. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0106] Amino acid residues 1-19 of SEQ ID NO: 32 are a signal peptide, which is optionally excluded from the antibody fusion molecule. Accordingly, in some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1075 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0107] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1075 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0108] In some embodiments, there is a polypeptide or a drug conjugation moiety, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about
25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0109] In some embodiments, there is a polypeptide or a drug conjugation moiety, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0110] In some embodiments, there is a polypeptide or a drug conjugation moiety that comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1072 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1072 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 480-1072 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 480- 1072 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1064 of SEQ ID NO: 32. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1064 of SEQ ID NO: 32.
[0111] In some embodiments, there is a polypeptide or drug conjugation moiety that comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or
99% identical to residues 465-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 483-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 483- 1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1067 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465- 1067 of SEQ ID NO: 33.
Antibody Fusion Molecule Drug Conjugates
[0112] The antibody fusion molecules described herein can further include a payload molecule, such as a drug molecule, covalently bound to the cysteine residue in any one or more of the heterologous peptides through a conjugation linker. The number of payload molecules attached to the antibody fusion molecule can be determined based on the number of heterologous peptides comprising cysteines, and the number of drug molecules that are conjugated to each cysteine.
[0113] The payload molecule can be a hydrophobic payload molecule, such as a hydrophobic drug molecule. In some embodiments, the payload molecule has a solubility of about 10 mg/mL or less, about 5 mg/mL or less, about 2.5 mg/mL or less, about 1 mg/mL or less, about 0.5 mg/mL or less, about 0.2 mg/mL or less, about 0.1 mg/mL or less, about 0.005 mg/mL or less, about 0.02 mg/mL or less, or about 0.01 mg/mL or less) in water at pH 7 at 25 °C.
[0114] In some embodiments, the payload molecule is a drug molecule. In some
embodiments, the drug molecule is a cytotoxic drug, an anti-viral drug, or an anti-bacterial drug. Exemplary drugs that can be conjugated to the antibody fusion molecule includes an antibiotic, a microtubule disrupting agent, a DNA modifying agent, an RNA polymerase inhibitor, or a topoisomerase I inhibitor. In some embodiments, the drug is azaribine, anastrozole, azacitidine, bleomycin, bortezomib, bryostatin-l, busulfan, camptothecin, 10- hydroxycamptothecin, calicheamicin, carmustine, celebrex, chlorambucil, cisplatin, irinotecan, carboplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, docetaxel, dactinomycin, daunomycin glucuronide, daunorubicin, dexamethasone, diethylstilbestrol,
doxorubicin, doxorubicin glucuronide, duocarmycin, duomycin, epirubicin, ethinyl estradiol, estramustine, etoposide, etoposide glucuronide, floxuridine, fludarabine, flutamide, fluorouracil, fluoxymesterone, gemcitabine, hydroxyprogesterone caproate, hydroxyurea, idarubicin, ifosfamide, leucovorin, lomustine, mechlorethamine, medroxyprogesterone acetate, megestrol, melphalan, mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), paclitaxel, phenylbutyrate, prednisone, procarbazine, paclitaxel, pentostatin,
pyrrolobenzodiazepine (PBD), semustine, SN-38, streptozocin, tamoxifen, a taxane, testosterone propionate, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vinblastine, vinorelbine, or vincristine. In some embodiments, the payload molecule is an imaging agent, such as a fluorescent imaging agent or an MRI contrast agent.
[0115] In some embodiments, the antibody fusion molecule includes one or more payload molecules, such as 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more payload molecules. In some embodiments, the antibody fusion molecule includes 2 to 30 payload molecules, such as 2 to 4, 4 to 8, 8 to 12, 12 to 16, 16 to 20, 20 to 25, or 25 to 30 payload molecules.
[0116] The payload molecule can be conjugated to the cysteine on the heterologous peptide through any suitable conjugation linkers. In some embodiments, the payload molecule is conjugated to the cysteine through a maleimide moiety (i.e., through maleimide alkylation) or through cysteine arylation (e.g., through the use of a palladium complex). In some embodiments, the maleimide moiety is a N-alkyl maleimide moiety. Binding of the maleimide moiety to the thiol of the cysteine results in a succinimide thioether, which can be hydrolyzed into a ring-opened counterpart.
[0117] In some embodiments, the conjugation linker is not cleavable. Payload molecules, such as drug molecules, conjugated to the antibody fusion molecule through a non-cleavable linker are leased after the antibody fusion molecule is internalized by the target cell and the polypeptide components of the antibody fusion molecule are degraded by the lysosome.
[0118] In some embodiments, the conjugation linker is a cleavable linker. Exemplary cleavable linkers may include a pH- sensitive cleavable linker (such as a linker with a hydrazine moiety which is cleavable in acidic conditions), an enzymatically cleavable linker, such as a linker with a protease-cleavable moiety (such as a valine-alanine (Val-Ala) dipeptide component or a valine-citrulline dipeptide component, which may be
/; - a m i n o b e n zy 1 o x y c a r b o n y 1 (PABC)), linker cleavable under reducing conditions (such as a linker having a disulfide bond, which is cleavable in intracellular reducing conditions), or a
pyrophosphate diester. Exemplary conjugation linkers for conjugating the drug to a cysteine in the heterologous peptide are discussed in Tsuchikama et ah, Antibody-drug conjugates: recent advances in conjugation and linker chemistries, Protein & Cell, vol. 9, pp. 33-46 (2018), first available online Oct. 14, 2016.
[0119] An exemplary conjugation linker that can be used to conjugate the payload to the cysteine of the heterologous peptide is shown in Formula I:
wherein z is 4-24; and the maleimide group is covalently attached to the cysteine of the heterologous peptide through the maleimide group.
[0120] In some embodiments, the conjugation linker conjugated to the cysteine of the heterologous peptide is bound to two or more payload molecules. The two or more payload molecules may optionally be independently cleavable from the conjugation linker, for example by including a cleavable bond for each payload molecule.
[0121] In some embodiments, there is an antibody fusion molecule, comprising antigen binding moiety that binds to DLL3, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl), wherein the heterologous peptide comprises a cysteine residue conjugated to a DNA- modifying agent. In some embodiments, the DNA-modifying agent is pyrrolobenzodiazepine (PBD), a PBD dimer, calicheamicin, duomycin, or duocarmycin. In some embodiments, the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
[0122] In some embodiments, there is an antibody fusion molecule, comprising antigen binding moiety that binds to Trop-2, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl), wherein the heterologous peptide comprises a cysteine residue conjugated to a topoisomerase inhibitor. In some embodiments, the topoisomerase inhibitor is SN-38. In some
embodiments, the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
[0123] In some embodiments, there is an antibody fusion molecule, comprising antigen binding moiety that binds to Claudin 18.2, but not to Claudin 18.1, or binds to Claudin 18.1 with at least 10 times weaker binding affinity than to Claudin 18.2, comprising an antibody heavy chain and an antibody light chain or fragment thereof and a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) , wherein the heterologous peptide comprises a cysteine residue conjugated to a DNA-modifying agent, a microtubule disrupting agent, or a topoisomerase inhibitor. In some embodiments, the cysteine residue is conjugated to monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), SN-38, PBD, a PBD dimer, calicheamicin, duomycin, or duocarmycin. In some embodiments, the drug conjugation moiety comprises an albumin or an albumin fragment fused to the heterologous peptide, either at the N-terminal end or the C-terminal end of the heterologous peptide.
[0124] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), wherein the heterologous peptide comprises a cysteine residue conjugated to a payload molecule (such as a drug molecule, for example a cytotoxic drug molecule). In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0125] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less
than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen binding moiety comprises an antibody fragment. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0126] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0127] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, the drug conjugation moiety is fused to the antigen -binding moiety via Pl. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via the albumin or the albumin fragment. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0128] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising an antibody heavy chain, or a fragment thereof, and an antibody light chain, or a fragment thereof; and drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine.
In some embodiments, Pl is charged. In some embodiments, the drug conjugation moiety is fused to the antibody heavy chain or fragment thereof. In some embodiments, the drug
conjugation moiety is fused to the antibody light chain or fragment thereof. In some embodiments, the antigen-binding moiety comprises a full length antibody. In some embodiments, the antigen-binding moiety comprises an antibody fragment. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0129] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody heavy chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0130] In some embodiments, an antibody fusion molecule comprises an antigen-binding moiety comprising two full-length antibody heavy chains and two full-length antibody light chain; and a drug conjugation moiety fused to the C-terminus of each antibody light chain, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a payload molecule, such as a drug molecule (such as a cytotoxic drug molecule), (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some
embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, the drug conjugation moiety is fused to the antigen-binding moiety via P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged.
In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0131] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0132] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0133] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide
comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0134] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 32, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1072 of SEQ ID NO: 32, residues 480-1072 of SEQ ID NO: 32, or residues 465-1064 of SEQ ID NO: 32 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain
variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0135] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1072 of SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0136] In some embodiments, the antibody fusion molecule, comprising an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1072 of SEQ ID NO: 32, wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the payload molecule is conjugated to Cysl070 of SEQ ID NO: 32. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0137] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 33, wherein a payload molecule is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is
conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO:
14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0138] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0139] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising CDR1, CDR2, and CDR3 of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion
molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0140] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antigen binding moiety comprises an antibody light chain or antibody light chain fragment, and an antibody heavy chain or antibody heavy chain fragment comprising the antibody heavy chain variable region of the sequence according to SEQ ID NO: 33, wherein the antigen binding moiety is fused to a polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33, and wherein a payload molecule, such as a drug molecule, is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody heavy chain or antibody heavy chain fragment. In some embodiments, the polypeptide comprising residues 465-1075 of SEQ ID NO: 33, residues 483-1075 of SEQ ID NO: 33, or residues 465-1067 of SEQ ID NO: 33 is fused to the antibody light chain or antibody light chain fragment. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule
comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0141] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 20-1075 of SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some
embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0142] In some embodiments, the antibody fusion molecule comprises an antigen binding moiety that specifically binds to GPC3, wherein the antibody fusion molecule comprises an antibody light chain and a polypeptide comprising a sequence according to residues 20-1075 of SEQ ID NO: 33, wherein a drug molecule is conjugated to the polypeptide. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the antibody fusion molecule comprises an antibody light chain or antibody light chain fragment comprising CDR1, CDR2, and CDR3 of the antibody light chain according to SEQ ID NO: 14. In some embodiments, the antibody fusion molecule comprises an antibody light chain variable region comprising the antibody light chain variable region of the antibody light chain according to SEQ ID NO: 14. In some
embodiments, the antibody fusion molecule comprises an antibody light chain comprising a sequence according to SEQ ID NO: 14.
[0143] In some embodiments, there is a polypeptide or drug conjugation moiety, comprising (1) a heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a drug molecule, and (2) an albumin or an albumin fragment fused to Pl. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin.
In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of Pl. In some embodiments, Pl is charged. In some embodiments, Pl comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0144] In some embodiments, there is a polypeptide or drug conjugation moiety, comprising (1) a first heterologous peptide (Pl) less than about 50 amino acids in length (or less than about 40, or less than about 30, or less than about 20 amino acids in length), comprising a cysteine residue conjugated to a drug molecule, (2) an albumin or an albumin fragment fused to Pl, and (3) a second heterologous peptide (P2) fused to the albumin or the albumin fragment. In some embodiments, the cysteine residue of Pl is within about 30 amino acids (such as within about 25, within about 20, within about 15, or within about 10 amino acids) of the albumin or albumin fragment. In some embodiments, the albumin is a full length albumin. In some embodiments, the albumin or albumin fragment is fused to the N-terminus of Pl. In some embodiments, the albumin or albumin fragment is fused to the C-terminus of P2. In some embodiments, P2 does not comprise a cysteine. In some embodiments, Pl is charged. In some embodiments, Pl or P2 comprises one or more contiguous linkers having the sequence GGGGS (SEQ ID NO: 42).
[0145] In some embodiments, there is a polypeptide or drug conjugation moiety comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 480-
1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 480-1072 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465- 1064 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1064 of SEQ ID NO: 32, wherein the polypeptide or drug conjugation moiety is conjugated to a drug molecule. In some embodiments, the drug molecule is conjugated to Cysl070 of SEQ ID NO: 32.
[0146] In some embodiments, there is a polypeptide or drug conjugation moiety comprising a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 483-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 483-1075 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to residues 465- 1067 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a sequence according to residues 465-1067 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cys477 of SEQ ID NO: 33. In some embodiments, the drug molecule is conjugated to Cysl073 of SEQ ID NO: 33. In some embodiments, the polypeptide or drug conjugation moiety comprises a first drug molecule conjugated to Cys477 of SEQ ID NO: 33 and a second drug molecule conjugated to Cysl073 of SEQ ID NO: 33.
Pharmaceutical Compositions
[0147] Pharmaceutical compositions of the antibody fusion molecules and antibody fusion molecule drug conjugates are prepared by mixing the antibody fusion molecules or the antibody fusion molecule drug conjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (see Remington's Pharmaceutical
Sciences l6th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG).
[0148] Buffers are used to control the pH in a range which optimizes the therapeutic effectiveness, especially if stability is pH dependent. Buffers are preferably present at concentrations ranging from about 50 mM to about 250 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof, such as citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate. Additionally, buffers may comprise histidine and trimethylamine salts such as Tris.
[0149] Preservatives are added to retard microbial growth, and are typically present in a range from 0.2% - 1.0% (w/v). Suitable preservatives for use with the present invention include octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
benzalkonium halides (e.g., chloride, bromide, iodide), benzethonium chloride; thimerosal, phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol, 3-pentanol, and m-cresol.
[0150] Tonicity agents, sometimes known as“stabilizers” are present to adjust or maintain the tonicity of liquid in a composition. When used with large, charged biomolecules such as proteins and antibodies, they are often termed“stabilizers” because they can interact with the charged groups of the amino acid side chains, thereby lessening the potential for inter- and intra-molecular interactions. Tonicity agents can be present in any amount between 0.1% to 25% by weight, or more preferably between 1% to 5% by weight, taking into account the relative amounts of the other ingredients. Preferred tonicity agents include polyhydric sugar
alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol and mannitol.
[0151] Non-ionic surfactants or detergents (also known as“wetting agents”) are present to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody. Non-ionic surfactants are present in a range of about 0.05 mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2 mg/ml.
[0152] Suitable non-ionic surfactants include polysorbates (20, 40, 60, 65, 80, etc.), polyoxamers (184, 188, etc.), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. Anionic detergents that can be used include sodium lauryl sulfate, dioctyle sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.
[0153] The choice of pharmaceutical carrier, excipient or diluent may be selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) or solubilizing agent(s).
[0154] There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, pharmaceutical compositions useful in the present invention may be formulated to be administered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be administered by a number of routes.
[0155] In some embodiments, an antibody formulation is a lyophilized antibody formulation. In another embodiment, an antibody formulation is an aqueous antibody formulation.
Methods of Treatment
[0156] The antibody fusion molecule conjugated to a drug can be used to treat a disease, depending on the antigen bound by the antigen-binding domain and the drug conjugated to the heterologous peptide. In some embodiments, the antibody fusion molecule drug conjugate is used to treat cancer, for example when the drug molecule is a cytotoxic agent. In
some embodiments, the antibody fusion molecule drug conjugate is used to treat an infection, for example when the drug molecule is an antibacterial agent or an antiviral agent. Other diseases that may be treated include metabolic diseases (such as diabetes), bone diseases (such as osteoporosis), obesity, heart disease, or liver disease.
[0157] In some embodiments, a method of treating a disease (such as cancer, a viral infection, or a bacterial infection) in a subject comprises administering to the subject an effective amount of an antibody fusion molecule conjugated to a cytotoxic drug through a cysteine of the heterologous peptide.
[0158] In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a blood cancer. Exemplary cancers that may be treated include, but are not limited to, leukemia, lymphoma, kidney cancer, bladder cancer, urinary tract cancer, cervical cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, esophageal cancer, liver cancer, colorectal cancer, stomach cancer, squamous cell carcinoma, prostate cancer, pancreatic cancer, lung cancer, cholangiocarcinoma, breast cancer, and ovarian cancer. In some embodiments, the cancer has one or more mutant RAS family genes. In some embodiments, the cancer cell has upregulated macropinocytosis compared to a non- cancerous cell.
[0159] In some embodiments, the antibody fusion molecule conjugated to a drug is used to treat a bacterial infection. In some embodiments, the bacteria causing the bacterial infection is a drug-resistant bacteria. In some embodiments, the antigen-binding moiety binds to a bacterial antigen. In some embodiments, the drug conjugated to the antibody fusion molecule is an antibacterial agent.
[0160] In some embodiments, the antibody fusion molecule conjugated to a drug is used to treat a viral infection. In some embodiments, the virus causing the viral infection is hepatitis C (HCV), hepatitis B (HBV), human immunodeficiency virus (HIV), a human papilloma virus (HPV). In some embodiments, the antigen-binding moiety binds to a viral antigen. In some embodiments, the drug conjugated to the antibody fusion molecule is an anti-viral agent.
[0161] Generally, dosages and routes of administration of the nanoparticle composition are determined according to the size and condition of the subject, according to standard pharmaceutical practice. In some embodiments, the antibody fusion molecule is administered to a subject through any route, including orally, transdermally, by inhalation, intravenously, intra-arterially, intramuscularly, direct application to a wound site, application to a surgical site, intraperitoneally, by suppository, subcutaneously, intradermally, transcutaneously, by
nebulization, intrapleurally, intraventricularly, intra-articularly, intraocularly, or intraspinally. In some embodiments, the composition is administered to a subject intravenously.
[0162] In some embodiments, the dosage of the antibody fusion molecule conjugated to the drug is a single dose or a repeated dose. In some embodiments, the doses are given to a subject once per day, twice per day, three times per day, or four or more times per day. In some embodiments, about 1 or more (such as about 2, 3, 4, 5, 6, or 7 or more) doses are given in a week. In some embodiments, the antibody fusion molecule conjugated to the drug is administered weekly, once every 2 weeks, once every 3 weeks, once every 4 weeks, weekly for two weeks out of 3 weeks, or weekly for 3 weeks out of 4 weeks. In some embodiments, multiple doses are given over the course of days, weeks, months, or years. In some embodiments, a course of treatment is about 1 or more doses (such as about 2, 2, 3, 4, 5, 7,
10, 15, or 20 or more doses).
Methods of Making the Antibody Fusion Molecule
[0163] Polypeptides that include an antibody heavy chain (or fragment) or an antibody light chain (or fragment) fused to a drug conjugation moiety can be produced using recombinant DNA methods. Nucleic acid molecules encoding the fusion polypeptide can be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid molecules may be readily isolated and sequenced using conventional methods. The antibody light chain or fragment or the variable heavy chain or fragment, wherein the antibody heavy chain or the antibody light chain is fused to the drug conjugation moiety, may be co-expressed in the same host cell. Suitable host cells for cloning or expression of fusion polypeptide vectors include prokaryotic cells or eukaryotic cells. Exemplary host cells include Chinese Hamster Ovary (CHO) cells or human embryonic kidney cells (e.g.,
HEK293).
[0164] Expression host cells express the antibody fusion molecule. After an expression period, the host cells can by lysed and the antibody fusion molecule purified. Exemplary purification methods include liquid chromatography, such as ion exchange chromatography, affinity chromatography (such as Protein A affinity chromatography), or size exclusion chromatography.
[0165] Drug molecules can be attached to a conjugation linker, for example during synthesis of the drug molecule or through a conjugation chemistry. The linker can include, for example, a maleimide moiety, which can react with a thiol group. The drug attached to the conjugation linker can be combined with the purified antibody fusion molecule, such that the
drug molecule conjugates to a cysteine of one of the heterologous peptides comprising a cysteine. The maleimide moiety reacts with the cysteine residue in the heterologous peptide to form a succinimide thioether. The ring in the succinimide thioether can open after hydrolysis, thereby forming a stable conjugation between the heterologous peptide and the drug.
[0166] In some embodiments, the conjugation linker is conjugated to the antibody fusion molecule prior to attaching the conjugation linker to the drug.
[0167] The drug can be conjugated to the antibody fusion molecule by mixing the antibody fusion molecule and the drug in solution. The drug is generally mixed with the antibody fusion molecule in molar excess (that is, a molar ratio of drug to antibody fusion molecule of about 1 or more). In some embodiments, the molar ratio of drug to antibody fusion molecule is about 1 to about 1 or more, about 2 or more, about 3 or more, about 4 or more, about 5 or more, about 6 or more, about 7 or more, or about 8 or more. In some embodiments, the molar ratio of drug to antibody fusion molecule is about 1 to about 20, about 2 to about 15, about 4 to about 10, or about 6 to about 8.
[0168] The antibody fusion molecule can be conjugated to the drug with or without mixing the antibody fusion molecule with a reducing agent. Exemplary reducing agents that may be used include tris (2-carboxyethyl)phosphine (TCEP), b-mercaptoethanol (B-ME) and dithiothreitol (DTT). The reducing agent can be mixed with the antibody fusion molecule to reduce thiolates on the protein prior to conjugating the drug to the antibody fusion molecule. The reducing agent may be mixed with the antibody fusion molecule at a molar ratio
(reducing agent to antibody fusion molecule) of about 1 or more, about 1.5 or more, about 2 or more, about 2.5 or more, about 3 or more, about 5 or more, about 10 or more, about 15 or more, or about 20 or more. In some embodiments, the reducing agent is mixed with the antibody fusion molecule at a molar ratio (reducing agent to antibody fusion molecule) of about 1 to about 100, about 2 to about 75, about 5 to about 50, about 10 to about 40, or about 20 to about 30. In some embodiments, the reducing agent is removed from the composition containing the antibody fusion molecule prior to conjugating the drug to the antibody fusion molecule. After treating the antibody fusion molecule with the reducing agent, the antibody fusion molecule is optionally treated with an oxidizing agent prior to conjugating the antibody fusion molecule with the drug. Exemplary oxidizing agents can include ascorbic acid, cysteine, oxidized glutathione, and copper ions.
[0169] Once the antibody fusion molecule is conjugated to a drug molecule, the antibody fusion molecule can be further purified, for example to isolate the antibody fusion molecule
conjugated to the drug from unreacted polypeptides, unreacted drug molecules, or antibody fusion molecules that are over- or under- conjugated to the drug molecules. Exemplary purification methods include liquid chromatography, such as ion exchange chromatography, affinity chromatography (such as Protein A affinity chromatography), or size exclusion chromatography. The purification methods can be used to isolate antibody drug conjugate molecules with a uniform drug-antibody ratio (DAR).
EXAMPLES
[0170] The following non-limiting examples are provided for illustrative purposes only in order to facilitate a more complete understanding of representative embodiments now contemplated. These examples are intended to be a mere illustration only and not to constitute a limitation on the scope of the invention. Thus, these examples should not be construed to limit any of the embodiments described in the present specification.
Example 1: Expression and Purification of Antibody- Albumin Fusion Protein
[0171] Expression plasmid constructs containing DNA sequences encoding the genes of the GPC3 antibody light chain (SEQ ID NO: 14) and antibody heavy chain-albumin fusion protein (SEQ ID NO: 33) were transfected into HEK-293 cells using polyethylenimine (PEI) for transient expression. The transfected cells were treated with valproic acid (VPA) 24 hours post transfection to enhance protein expression. The supernatants were harvested on day 6 and the antibodies were purified.
[0172] The antibody- albumin fusion protein was first captured by a Protein A affinity column, and eluted using a 0.5 M arginine buffer, pH 3.8. The pH of the eluted antibody- albumin fusion protein was adjusted to ~5.6, and the pH-adjusted elute was filtered. The antibody fusion protein was further purified by an anion exchange chromatography using Capto Q Impres resin. The purified antibody- albumin fusion protein was the formulated in a formulation containing 12 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7. It was stored at 2-8 °C or -80 °C until use.
Example 2: Drug Conjugation to Antibody- Albumin Fusion Protein
[0173] The antibody- albumin fusion protein expressed and purified as described in Example 1 was conjugated to MC-vc-PAB-MMAE (FIG. 1) according to the methods described in Reactions A-E, below.
[0174] Reaction A. The antibody- albumin fusion protein expressed and purified as described in Example 1 was conjugated to MC-vc-PAB-MMAE in the fusion protein storage buffer (2 mM Histidine, 4% mannitol, 2% sucrose, pH 6.7). The resulting antibody solution was adjusted to a concentration of >3 mg/mL. The presence of free, accessible thiols for cysteine- maleimide conjugation was measured using a standard Ellman’s reagent assay (ThermoFisher Scientific, Catalog # 22582). Briefly, Ellman’s reagent stock solution was prepared in DMSO at 0.1M before 1: 100 dilution into conjugation buffer. An equal volume of antibody aliquot and 1 mM Ellman’s reagent solution were mixed and incubated at room temperature for 5 min. The resulting absorbance was measured at 412 nm on a NanoDrop or Denovix instrument relative to buffer or suitable negative control. The ratio of free thiol-to-antibody (SH/Ab) was determined using Ellman’s reagent product extinction coefficient at 412 nm (e = 14,150 M^cnT1). Immediately prior to conjugation, but before drug-linker addition, propylene glycol (PG) was added to the antibody solution to give a final concentration of 30% (v/v). Solid MC-vc-PAB-MMAE drug-linker reagent (Levena Biopharma U.S.) was first dissolved in DMSO at 5 mM concentration before being added in 4-8-fold molar excess to the PG-containing antibody solution. After thorough mixing, the resulting conjugation reaction was allowed to incubate at room temperature for a minimum of 1.5 h.
[0175] Reaction progress was monitored via hydrophobic interaction chromatography (HIC) on an Agilent 1100 HPLC system using a MAbPac™ HIC- 10 column (5 pm particles, 1000 A pore size, 4.6 x 100 mm column, ThermoFisher Scientific, Catalog # 088480). The column temperature was set to 30 °C and a flow rate was set at 1 mL/min. The column was loaded with approximately 50-100 pg protein for analysis, and the column elute was monitored with by UV at wavelengths of 280 nm and 252 nm. The column was run with a gradient between Buffer A (1.5 M ammonium sulfate) and Buffer B (25 mM sodium phosphate, pH 7.0, 25% isopropanol) according to the following: 0 min, 0% Buffer B, to 24 min: 80% Buffer B; then 95% Buffer B to 30 min; 0% Buffer B. FIG. 2 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction A.
[0176] The A280 peaks indicating conjugate formation were measured relative to unmodified antibody and drug-linker control injections. Average DAR (drug-to-antibody ratio) and %
unmodified antibody-albumin fusion protein were determined via A280 peak area integration. The drug-antibody ratio (DAR) was calculated using the following equitation:
Fusion Protein
A -252 _
252 A 280 Fusion Protein
[MMAE] MMAE
DAR = '252
[Fusion Protein] MMAE
fc280
A280 A 252 MMAE
Fusion Protein
fc280
wherein the extinction coefficients (e) are defined in Table 2:
Table 2: Extension Coefficients for Determining Drug-Antibody Ratio (DAR)
[0177] Reaction B. The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)). The antibody- albumin fusion protein was conjugated to MC-vc-PAB-MMAE in the conjugation buffer as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A. FIG. 3 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction B.
[0178] Reaction C. The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)) before being partially reduced using 2.5x molar ratio of the reducing reagent tris(2-carboxyethyl)phosphine (TCEP). The conjugation reaction was conducted using 8x of MC-vc-PAB-MMAE at room temperature for
approximately 1 hour, as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A. FIG. 4 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction C.
[0179] Reaction D. The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4
mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra- 4 10 KDa centrifugal filter units (Millipore Sigma)) before being reduced using 20x molar ratio of the reducing reagent TCEP. The antibody-albumin fusion protein was then incubated with TCEP for 48 hours at 2-8 °C to fully reduce the antibody- albumin fusion protein. The TECP was removed and free thiol content was measured. The conjugation reaction was conducted using 4x of MC-vc-PAB-MMAE at room temperature for approximately 1 hour, as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A. FIG. 5 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction D.
[0180] Reaction E. Reaction D. The antibody- albumin fusion protein expressed and purified as described in Example 1 was buffer exchanged into conjugation buffer (50 mM sodium phosphate, 4 mM EDTA, pH 7.0) using multiple rounds of centrifugal ultrafiltration (using Amicon Ultra-4 10 KDa centrifugal filter units (Millipore Sigma)) before being reduced using 20x molar ratio of the reducing reagent TCEP. The antibody- albumin fusion protein was then incubated with TCEP for 48 hours at 2-8 °C to fully reduce the antibody- albumin fusion protein. The antibody-albumin fusion protein was then partially re-oxidized using ascorbic acid at room temperature for 1 hour. The conjugation reaction was conducted using 8x of MC-vc-PAB-MMAE at room temperature for approximately 1 hour, as otherwise described for Reaction A, and the product analyzed by HIC-HPLC as described for Reaction A. FIG. 6 shows the HIC-HPLC chromatograph of the protein-drug conjugate formed by Reaction E.
[0181] The reaction conditions and results for Reactions A-E are summarized in Table 3.
Table 3: Antibody-Albumin-Drug Conjugation Results Summary
[0182] While reactivity demonstrated with different equivalents of reducing agent (TCEP), highest DAR was achieved with the partial re-oxidation of fully reduced antibody- albumin fusion protein sample (Reaction E).
[0183] It is understood that although aspects of the present specification are highlighted by referring to specific embodiments, one skilled in the art will readily appreciated that these disclosed embodiments are only illustrative of the principles of the subject matter disclosed herein. Therefore, it should be understood that the disclosed subject matter is not intended to be limited to a particular compound, composition, article, or method, unless expressly stated as such. In addition, those of ordinary skill in the art will recognize that certain changes, modification, permutations, alterations, additions, subtractions, and sub-combinations thereof can be made in accordance with the teachings herein without departing from the spirit of the present specification.
Claims
1. An antibody fusion molecule, comprising:
an antigen-binding moiety comprising an antibody heavy chain and an antibody light chain, or a fragment thereof; and
a drug conjugation moiety fused to the antibody heavy chain or the antibody light chain or fragment thereof, wherein the drug conjugation moiety comprises a heterologous peptide (Pl) less than about 50 amino acids in length, and wherein Pl comprises a cysteine residue.
2. The antibody fusion molecule of claim 1, wherein the heterologous peptide (Pl) is unstructured or helical.
3. The antibody fusion molecule of claim 1 or 2, wherein the heterologous peptide (Pl) is about 5 to about 20 amino acids in length.
4. The antibody fusion molecule of any one of claims 1-3, wherein the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody heavy chain, or the fragment thereof.
5. The antibody fusion molecule of any one of claims 1-3, wherein the drug conjugation moiety is fused to the N-terminus or the C-terminus of the antibody light chain, or the fragment thereof.
6. The antibody fusion molecule of any one of claims 1-5, wherein the antigen-binding moiety comprises a full length antibody or an antibody fragment.
7. The antibody fusion molecule of any one of claims 1-6, wherein the drug conjugation moiety comprises an albumin or an albumin fragment fused to Pl.
8. The antibody fusion molecule of claim 7, wherein the cysteine residue of Pl is about 30 amino acid residues or less away from a first residue or a last residue of the albumin or the albumin fragment.
9. The antibody fusion molecule of claim 7 or 8, wherein the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the albumin or the albumin fragment.
10. The antibody fusion molecule of claim 7 or 8, wherein the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via Pl.
11. The antibody fusion molecule of any one of claims 7-10, wherein the albumin or the albumin fragment has a point mutation at Cys34.
12. The antibody fusion molecule of claim 11, wherein the point mutation is Cys34Ser.
13. The antibody fusion molecule of any one of claims 7-12, wherein the drug conjugation moiety comprises a full length albumin.
14. The antibody fusion molecule of any one of claims 7-12, wherein the drug conjugation moiety comprises an albumin fragment.
15. The antibody fusion molecule of any one of claims 7-14, wherein the drug conjugation moiety comprises a second heterologous peptide (P2), which is fused to the albumin or albumin fragment.
16. The antibody fusion molecule of claim 15, wherein the drug conjugation moiety is fused to the antibody heavy chain or antibody light chain or fragment thereof via the second heterologous peptide (P2).
17. The antibody fusion molecule of claim 15 or 16, wherein the second heterologous peptide (P2) comprises a cysteine residue.
18. The antibody fusion molecule of claim 15 or 16, wherein the second heterologous peptide (P2) does not comprise a cysteine residue.
19. The antibody fusion molecule of any one of claims 15-18, wherein the second heterologous peptide (P2) is helical or unstructured.
20. The antibody fusion molecule of anyone of claims 7-19, wherein the drug conjugation moiety comprises two or more albumins or albumin fragments.
21. The antibody fusion molecule of claim 20, wherein the drug conjugation moiety comprises three or more heterologous peptides.
22. The antibody fusion molecule of claim 21, wherein each of the heterologous peptides comprises a cysteine residue.
23. The antibody fusion molecule of any one of claims 1-22, comprising a polypeptide configured, from N-terminus to C-terminus, according to:
HL-P1;
HL-P1-A
HL-P1-A-P3;
HL-P1-A-P3-A;
HL-P 1 - A-P3 - A-P4 ;
HL-P 1 - A-P3 - A-P4- A;
HL-P 1 - A-P3 - A-P4- A-P5 ;
HL-P2-A-P1;
HL-P2-A-P1-A;
HL-P2- A-P 1 - A-P3 ;
HL-P2- A-P 1 - A-P3 - A; or
HL-P2- A-P 1 - A-P3 - A-P4 ;
wherein HL is the antibody heavy chain or the antibody light chain, or the fragment thereof;
wherein Pl, P3, P4, and P5 are heterologous peptides, wherein at least one of Pl, P3, P4, and P5 comprises a cysteine residue;
wherein P2 is a heterologous peptide; and
wherein A is an albumin or a fragment thereof.
24. The antibody fusion molecule of any one of claims 15-23, wherein the second heterologous peptide (P2) is about 5 to about 20 amino acid residues in length.
25. The antibody fusion molecule of any one of claims 15-24, wherein the second heterologous peptide (P2) comprises one or more glycine residues or one or more serine residues.
26. The antibody fusion molecule of any one of claims 15-25, wherein the second heterologous peptide (P2) comprises an amino acid sequence of (GGGGS)q (SEQ ID NO: 34), wherein q is 1, 2, 3, 4, or more.
27. The antibody fusion molecule of any one of claims 23-26, wherein each of Pl, P3, P4, and P5 is about 5 to about 20 amino acid residues in length, and wherein Pl, P3, P4, and P5 are of the same length or of different lengths.
28. The antibody fusion molecule of any one of claims 1-27, wherein at least one of Pl, P3, P4, and P5 comprises at least one charged amino acid.
29. The antibody fusion molecule of any one of claims 1-28, wherein at least one of Pl, P3, P4, and P5 comprises one or more positively charged amino acid residues.
30. The antibody fusion molecule of claim 29, wherein the one or more positively charged amino acid residues are selected from the group consisting of lysine, histidine, arginine, and combinations thereof.
31. The antibody fusion molecule of any one of claims 1-28, wherein at least one of Pl, P3, P4, and P5 comprises one or more negatively charged amino acid residues.
32. The antibody fusion molecule of claim 31, wherein the one or more negatively charged amino acid residues are selected from the group consisting of aspartic acid, glutamic acid, and combinations thereof.
33. The antibody fusion molecule of any one of claims 1-32, wherein at least one of Pl, P3,
P4, and P5 comprises a sequence according to:
(GGGGS)nCXaalXaa2Xaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 35);
(GGGGS)nXaalCXaa2Xaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 36);
(GGGGS)nXaaiXaa2CXaa3Xaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 37);
(GGGGS)nXaaiXaa2Xaa3CXaa4Xaa5Xaa6(GGGGS)m (SEQ ID NO: 38);
(GGGGS)nXaalXaa2Xaa3Xaa4CXaa5Xaa6(GGGGS)m (SEQ ID NO: 39);
(GGGGS)„XaalXaa2Xaa3Xaa4Xaa5CXaa6(GGGGS)m (SEQ ID NO: 40); or
(GGGGS)nXaaiXaa2Xaa3Xaa4Xaa5Xaa6C(GGGGS)m (SEQ ID NO: 41);
wherein Xaai, Xaa2, Xaa3, Xaa3, X 3, and Xaa6 are each either a single amino acid, or none;
wherein Xaai, Xaa2, Xaa3, Xaa4, Xaa3, and Xaa6 has a net positive charge or a net negative charge;
wherein n = 0, 1, 2, 3, or 4;
wherein m = 0, 1, 2, 3, or 4; and
wherein the sequence of Pl, P3, P4, and P5 may be the same or different.
34. The antibody fusion molecule of claim 33, wherein X^i, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 comprise:
at least one positively charged amino acid residue and no negatively charged amino acid residues; or
at least one negatively charged amino acid residue and no positively charged amino acid residues.
35. The antibody fusion molecule of claim 33 or 34, wherein X^i, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are each either:
an amino acid selected from the group consisting of histidine, lysine, arginine, aspartic acid, glutamic acid, glycine, serine, and threonine; or
none.
36. The antibody fusion molecule of any one of claims 1-35, wherein the antibody fusion molecule comprises a full length antibody heavy chain or a full length antibody light chain.
37. The antibody fusion molecule of any one of claims 1-36, wherein the albumin has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.
38. The antibody fusion molecule of any one of claims 1-37, wherein the antibody fusion molecule comprises a first drug conjugation moiety fused to the antibody light chain, and a second drug conjugation moiety fused to the antibody heavy chain.
39. The antibody fusion molecule of any one of claims 1-38, further comprising a payload molecule covalently bound to the cysteine residue in any one or more of Pl, P3, P4, and P5.
40. The antibody fusion molecule of claim 39, wherein the payload molecule comprises a drug molecule or an imaging agent.
41. The antibody fusion molecule of claim 40, wherein the drug molecule comprises a cytotoxic drug molecule, an anti- viral agent, or an anti-bacterial agent.
42. The antibody fusion molecule of claim 40 or 41, wherein the antibody fusion molecule comprises 2-30 payload molecules.
43. The antibody fusion molecule of any one of claims 40-42, wherein the payload molecule is covalently bound to the cysteine residue in Pl, P3, P4, or P5 through a conjugation linker.
44. The antibody fusion molecule of claim 43, wherein the conjugation linker is bound to two or more payload molecules.
45. The antibody fusion molecule of claim 43 or 44, wherein the conjugation linker is not cleavable.
46. The antibody fusion molecule of claim 43 or 44, wherein the conjugation linker is cleavable.
47. The antibody fusion molecule of claim 39, wherein the payload molecule is MC-vc- PAB-MMAE or a conjugation product thereof.
48. The antibody fusion molecule of claim 47, wherein the antigen binding moiety specifically binds to GPC3.
49. The antibody fusion molecule of claim 48, wherein the antigen binding moiety comprises an antibody light chain with at least 95% identity to SEQ ID NO: 14, and an antibody heavy chain with at least 95% identity to SEQ ID NO: 32 or SEQ ID NO: 33.
50. The antibody fusion molecule of any one of claims 1-49, wherein the antigen-binding moiety binds to one or more antigens on the surface of a cancer cell.
51. The antibody fusion molecule of claim 50, wherein the cancer cell has upregulated macropinocytosis.
52. The antibody fusion molecule of claim 50 or 51, wherein the cancer cell comprises one or more mutant RAS family genes.
53. A pharmaceutical composition comprising an antibody fusion molecule of any one of claims 39-52, and a pharmaceutically acceptable excipient.
54. A method of treating a cancer in a subject, comprising administering to the subject with cancer an effective amount of the pharmaceutical composition according to claim 53, wherein the payload molecule is a cytotoxic drug.
55. The method of claim 54, wherein the cancer expresses an antigen targeted by the antibody or fragment thereof, and comprises a mutant RAS gene.
56. A method of making an antibody fusion molecule, comprising conjugating a payload molecule to the antibody fusion molecule according to any one of claims 1-55.
57. The method of claim 56, wherein the drug molecule is conjugated to a cysteine residue in Pl, P3, P4, or P5 through a conjugation linker.
58. The method of claim 57, wherein the conjugation linker is attaching to the payload molecule prior to attaching the conjugation linker to the cysteine residue in Pl, P3, P4, or P5.
59. The method of claim 57, wherein the conjugation linker is attached to the antibody fusion molecule prior to attaching the conjugation linker to the payload molecule.
60. The method of any one of claims 56-59, comprising mixing the antibody fusion molecule with a reducing agent prior to conjugating the payload molecule to the fusion molecule.
61. The method of claim 60, comprising mixing the antibody fusion molecule with an oxidizing agent after mixing the antibody fusion molecule with the reducing agent, and prior to conjugating the payload molecule to the fusion molecule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625709P | 2018-02-02 | 2018-02-02 | |
US62/625,709 | 2018-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019152827A1 true WO2019152827A1 (en) | 2019-08-08 |
Family
ID=67479948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/016325 WO2019152827A1 (en) | 2018-02-02 | 2019-02-01 | Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019152827A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021258A1 (en) * | 1994-02-01 | 1995-08-10 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fusion proteins that include antibody and nonantibody portions |
WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20090220502A1 (en) * | 2007-10-04 | 2009-09-03 | Brandt Cameron S | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
WO2013006706A1 (en) * | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
-
2019
- 2019-02-01 WO PCT/US2019/016325 patent/WO2019152827A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021258A1 (en) * | 1994-02-01 | 1995-08-10 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Fusion proteins that include antibody and nonantibody portions |
WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20090220502A1 (en) * | 2007-10-04 | 2009-09-03 | Brandt Cameron S | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS |
WO2013006706A1 (en) * | 2011-07-05 | 2013-01-10 | Bioasis Technologies Inc. | P97-antibody conjugates and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10436788B2 (en) | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells | |
JP6828950B2 (en) | Antibody-SN-38 immunoconjugate with CL2A linker | |
US9745374B2 (en) | Fusion proteins containing recombinant cytotoxic RNAses | |
JP6427789B2 (en) | Antibody-SN-38 immune complex with CL2A linker | |
US9770517B2 (en) | Anti-Trop-2 antibody-drug conjugates and uses thereof | |
US8420086B2 (en) | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases | |
US20210283269A1 (en) | Effective method for manufacturing antibody-drug conjugate | |
US20190381079A1 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
KR102342934B1 (en) | Antibody-drug conjugates and immunotoxins | |
TW201709932A (en) | CD123 antibodies and conjugates thereof | |
CA2947238A1 (en) | Site-specific conjugation of linker drugs to antibodies and resulting adcs | |
WO2015047510A1 (en) | Anti-trop-2 antibody-drug conjugates and uses thereof | |
CN117138060A (en) | New adjuvant use of antibody-drug conjugates | |
US20170326249A1 (en) | Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses | |
CN117295526A (en) | Method for preparing highly homogeneous antibody-drug conjugates of engineered antibodies | |
WO2022014698A1 (en) | Method for producing antibody-drug conjugate | |
US20170281791A1 (en) | Anti-trop-2 antibody-drug conjugates and uses thereof | |
WO2019152827A1 (en) | Novel antibody-drug conjugates (adc), methods of making, and methods of use thereof | |
WO2007084693A2 (en) | Immunoconjugates with improved efficacy for the treatment of diseases | |
US20240091372A1 (en) | Anti-doppel antibody drug conjugates | |
TW202200209A (en) | Modified binding polypeptides for optimized drug conjugation | |
TW202400644A (en) | BINDING MOLECULES AGAINST FRα | |
TW202348252A (en) | Combination therapies for treatment of cancer with therapeutic binding molecules | |
CN117180449A (en) | Preparation method of antibody drug conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19746923 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19746923 Country of ref document: EP Kind code of ref document: A1 |